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ABSTRACT OF DISSERTATION 
 
 
GENETIC MOUSE MODELS OF LIVER DISEASE: 
POTENTIAL ROLES OF ZHX2 (AFR1) AND AFR2 
IN DAMAGE AND REGENERATION 
 
The liver is the largest internal organ in mammals and responsible for carrying out 
various processes, including lipid and carbohydrate metabolism, detoxification of 
chemicals, and production of serum proteins. Liver damage, which can be caused by a 
variety of agents including viral infection, environmental toxins, alcohol and excessive 
dietary fats, can cause dysregulation of these critical functions, leading to worsening liver 
pathophysiology and impacting health. However, the liver has the remarkable ability to 
regenerate when damaged. Hepatocytes, which comprise a majority of liver cells, are 
relatively quiescent under healthy conditions. Upon injury, remaining hepatocytes can 
proliferate to recover from liver damage while performing their metabolic functions. 
Unfortunately, persistent injury can progressively lead to hepatitis, fibrosis, and 
ultimately end-stage liver disease, cirrhosis, and liver cancer. Overall, liver disease is the 
fifth leading cause of death worldwide and a growing healthcare problem in the United 
States and other western countries. A better understanding of liver regeneration could be 
used clinically to treat a wide range of liver diseases. 
 Studies in different mouse strains have provided genetic models to understand 
aspects of liver gene regulation and liver disease. Two regulators of the liver-derived 
serum protein alpha-fetoprotein (AFP), alpha-fetoprotein regulator 1 and 2 (Afr1 and 
Afr2), have been implicated to play a role in liver disease and regeneration. AFP is 
normally expressed in the fetal liver, silenced at birth, and reactivated in liver 
regeneration and liver cancer. Based on the unusually high AFP expression in adult 
BALB/cJ mice, our lab identified Zinc Fingers and Homeoboxes 2 (Zhx2) as the gene 
responsible for the Afr1 trait. BALB/cJ mice contain a natural mutation in the Zhx2 gene. 
Additional studies have shown that Zhx2 is involved in several liver diseases, including 
diet-induced fatty liver disease and hepatocellular carcinoma. In addition to these traits, 
BALB/cJ mice have been shown to have increased liver fibrosis after chronic treatment 
with the hepatotoxin carbon tetrachloride (CCl4). The locus responsible for this trait, 
called Hepatic fibrosis 1 (Hfib1), was mapped to the same region of Chromosome 15 
(Chr15) as Zhx2, but the Hfib1 gene has not been identified.  
During liver regeneration after acute treatment with CCl4, it was found that liver 
AFP mRNA levels were much higher in C3H/HeJ mice than in C57BL/6J mice. The 
locus that controls this strain-specific difference in AFP reactivation was called Afr2; 
C3H/HeJ and C57BL/6 mice are thought to contain the Afr2a and Afr2b alleles, 
respectively. The Afr2 locus has been mapped to Chr2, but the Afr2 gene has not been 
identified.  
  This dissertation tested the hypothesis that Zhx2 is responsible for the Hfib1 trait 
in BALB/cJ mice. Using BALB/cJ mice and C57BL/6J mice with a targeted mutation in 
the Zhx2 gene, my data indicates that Zhx2 is not responsible for the Hfib1 trait. Mice 
with low Zhx2 expression did not have more significant inflammation, liver damage, or 
     
 
fibrosis than mice with wild-type Zhx2 levels. These data suggest that another gene, 
presumably within the same region as Zhx2, is responsible for the Hfib1 phenotype in 
BALB/cJ mice. I also analyzed the Afr2 trait across several different strains of mice. My 
studies indicate that the strains 129X1/SvJ, C3H/HeJ, and DBA/2J contain the Afr2a 
allele, whereas mice in the C57 lineage (C57BL/6J, C57BL/6N, C57BL/10) contain the 
Afr2b allele. I also demonstrate that F1 offspring of 129X1/SvJ mice and C57BL/6J mice 
display an intermediate AFP reactivation phenotype, suggesting that the Afr2a and Afr2b 
alleles are co-dominant. These data provide the framework for future studies to identify 
the Afr2 gene. Taken together, my results indicate that regulators of gene expression 
within the liver, as defined by differences within mouse strains, can provide insight into 
liver disease and regeneration. 
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CHAPTER 1. INTRODUCTION 
1.1 The Liver 
The liver is the largest internal organ in mammals and carries out numerous 
functions, including multiple metabolic processes such as glucose metabolism and lipid 
homeostasis. The liver is a primary location for converting glucose into glycogen for 
energy storage, enabling it to be utilized later [1], and is the setting for glycolysis, the 
process of breaking down glucose to generate ATP for energy [2]. The liver is also 
responsible for producing the key enzymes responsible for gluconeogenesis, including 
phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase, and fructose 1,6-
biphosphate [3]. The liver is also the site for producing serum proteins, including 
numerous transport proteins such as albumin and alpha-fetoprotein (AFP) [4, 5].  
The liver also is essential for both lipid production and breakdown. Hepatocytes 
within the liver can generate lipid from excess glucose by converting the pyruvate 
produced during glycolysis into acetyl-CoA. The process of de novo lipogenesis (DNL) 
can use this acetyl-CoA to create fatty acids [3, 6, 7]. β-oxidation within the hepatocytes 
can break down lipids for energy. β-oxidation reduces the lipid chain to make acetyl-CoA 
within the mitochondria or peroxisomes, which can then be used for ATP production [3, 
6, 7]. 
The liver has an essential role in the metabolism and detoxification of numerous 
endogenous and exogenous compounds. Many enzymes within the liver are responsible 
for this process, categorized as Phase I, II, and III metabolizing enzymes. Phase I 
enzymes include those that have a primary role in oxidizing xenobiotics for subsequent 
breakdown [8, 9]. Cytochrome P450s (Cyp) are a family of proteins that are classified in 
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this group and are responsible for approximately 75-95% of the breakdown of the 
compounds that enter the liver from the bloodstream [10, 11]. Although this process has a 
vital role in eliminating toxic compounds, some of the metabolites from these reactions 
are more toxic than the original compounds [12, 13]. For example, environmental 
chemicals such as carbon tetrachloride (CCl4) can be converted by Cyp2E1 into highly 
reactive radical products trichloromethyl (CCl3ꞏ) and trichloromethyl peroxyl (CCl3OOꞏ), 
both of which can cause oxidative damage to cellular components [12, 14]. Cyps can 
metabolize compounds into carcinogens, like Diethylnitrosamine (DEN), which can 
cause initiate tumorigenesis in the liver [15]. This occurs after Cyp2E1 metabolizes DEN 
into the metabolite methyldiazohydroxide, which can create methylated guanine, creating 
DNA adducts [13]. In addition, Phase II metabolizing enzymes function as transferases 
and include the enzymes glutathione-s-transferases (GST), UDP-glucuronosyltransferases 
(UGT), sulfotransferases (SULT), among others [16]. Phase II enzymes can metabolize 
processes such as removing free radicals, conjugating to compounds to help with 
excretion, and metabolizing certain endogenous and exogenous compounds [9]. Phase III 
metabolizing enzymes serve as transporters for small and large compounds, including the 
transporters multidrug resistance-associated protein (MRP), P-glycoprotein (P-gp), and 
organic anion transporter (OAT) [17]. These transporters are important for shuttling 
nutrients and metabolites to targeted areas [18]. 
1.2 Liver Structure and Zonality 
Liver functions depend on the overall liver structure and the various cell types 
that comprise this organ. Hepatocytes, which comprise roughly 80% of total liver volume 
and ~60% of liver cells, carry out a majority of liver functions, including carbohydrate, 
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lipid, and drug metabolism processes [2, 19]. The resident macrophages, called Kupffer 
cells, make up the largest population of macrophages in the body. Kupffer cells are 
essential for innate immune responses both locally and throughout the body [20, 21]. In 
addition to the Kupffer cells, other immune cells include NK, neutrophils, and dendritic 
cells that are important for responding to liver injury [22]. The hepatic stellate cells are 
generally quiescent pericytes that serve as the body’s primary location for Vitamin A 
storage. However, persistent liver damage results in the activation of stellate cells into 
myofibroblasts, which produce several extracellular matrix proteins that contribute to 
liver fibrosis [23]. Liver sinusoidal endothelial cells line the blood vessels, playing an 
important role in regulating blood flow [24]. Cholangiocytes line the bile ducts and are 
critical for delivering bile acids from the liver to the GI tract [25]. 
The liver architecture is organized into repeating hexagonal units called lobules. 
At the middle of each lobule is the central vein, whereas each axis of the hexagon 
consists of a portal triad, which is comprised of a portal vein, hepatic artery, and bile duct 
[26] (Figure 1.1 A). On average, the distance between the central veins and portal triads 
spans roughly 15 hepatocytes. Blood enters the liver through the portal vein and hepatic 
artery rich in nutrients from the GI tract and oxygen from the heart, respectively. The 
blood then travels through a sinusoidal space between plates of hepatocytes lined by a 
layer of endothelial cells. During this time, the exchange of materials between the 
bloodstream and hepatocytes occurs [27] (Figure 1.1 B). 
Many functions within the liver are managed, in large part, by a phenomenon 
called metabolic zonation. Hepatocytes within the liver carry out distinct functions based 
on their location within the liver lobule. The region surrounding the portal triad, called 
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zone 1 or the periportal region, contains hepatocytes that perform oxygen-dependent 
processes such as lipolysis, glucogenesis, and cholesterol synthesis [28, 29]. The region 
surrounding the central vein, called zone 3 or pericentral region, contains hepatocytes that 
carry out glycolysis and lipogenesis [28, 30] (Figure 1.1 C). Thus, the expression of 
subsets of hepatic genes is based on their location within the lobule [31]. Pericentrally 
expressed genes are involved in glycolysis (glyceraldehyde-3-phosphate dehydrogenase, 
glucose-6-phosphate isomerase), glutamine synthesis (glutamine synthetase), and drug 
metabolism (Cyp2e1) [30, 32]. In addition, periportal hepatocytes express genes crucial 
for gluconeogenesis (phosphoenolpyruvate carboxykinase, tyrosine aminotransferase), 
fatty acid oxidation (acetyl-CoA carboxylase), and bile acid formation (carnitine 
palmitoyltransferase 1) [29, 33-35]. Genes expressed in zone 2, which is intermediate 
between zones 1 and 3, are not known to have roles in specific metabolic processes but 
have recently been speculated to play a role in liver homeostasis [36]. Although some 
genes display strict or gradient zonal expression, some genes are not zonally expressed 
[28, 34]. A significant contributor to liver zonation is Wnt/β-catenin signaling. Active -
catenin protein is normally only found in pericentral hepatocytes; this restricted 
expression is due to certain Wnt proteins that are synthesized by endothelial cells 
surrounding the central veins. When the β-catenin gene is deleted in hepatocytes, 
pericentral genes are no longer expressed and liver regeneration is diminished [32]. In 
contrast, deletion of the Adenomatous Polyposis Coli (APC) gene, which is part of a 
complex that phosphorylates β-catenin in the periportal hepatocytes, leading to its 
degradation, results in expression on pericentral genes in all hepatocytes [33]. In a 2019 
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single-cell transcriptomics paper, reductions in zonal expression were found to be due to 
reductions in Wnt secretion and signaling [28]. 
1.3 Liver Injury and Disease 
The adult liver is usually a quiescent organ under healthy conditions with very 
low cell turnover. However, hepatocytes can be damaged or killed by various agents, 
leading to liver disease. These agents include viral infection [primarily Hepatitis B Virus 
(HBV) and HCV], excessive alcohol consumption, obesity-related fatty acid 
accumulation, environmental toxins, pharmaceutical drugs, and autoimmune disorders. 
The liver normally recovers from acute damage with minimal impact on liver function, as 
described below, but persistent damage can lead to progressive liver disease. Persistent 
damage, such as HBV infection, can lead to inflammation that, if it persists, may lead to 
permanent damage and worsen liver function [37]. Chronic alcohol consumption can also 
lead to advanced liver disease. In 2017 the mortality rates for alcoholic liver cirrhosis 
were 6.8 per 100,000 people [38]. In recent years, obesity rates have been steadily rising, 
increasing many obesity-related diseases. Obesity can lead to a condition known as non-
alcoholic fatty liver disease (NAFLD), which has rapidly become one of the most 
common causes of liver disease in the United States and other western countries. It is 
estimated that approximately 31% of adult Americans have some form of NAFLD [39]. 
Some autoimmune disorders, including autoimmune liver disease, primary sclerosing 
cholangitis, and primary biliary cirrhosis, can also cause patients to develop hepatitis that 
can further diminish liver function [40]. Immune cells can lose self-tolerance and target 
hepatocytes of immunocompromised patients, leading to worsening liver damage if 
persistent environmental or internal stimuli continue [41].  
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Liver disease can range in a spectrum of severity. Hepatic steatosis, the initial 
stage of liver disease, is hallmarked by lipid accumulation within the hepatocytes [42]. 
This increase in lipid droplets is associated with developing NAFLD, alcoholic, and drug-
induced fatty liver disease [42]. Non-alcoholic fatty liver-caused steatosis develops as the 
result of multiple factors. The “multi-hit hypothesis” proposes that disease starts with an 
accumulation of lipids dependent on insulin resistance development [43]. The first hit 
results from insulin resistance and is associated with increases in DNL in the liver leading 
to elevated fatty acid production [44]. The secondary hit is when steatosis develops 
inflammation, a condition known as steatohepatitis. Oxidative stress is a crucial player in 
this second hit, causing the accumulation of proinflammatory cells and activation of 
stellate cells, which combine to promote fibrosis [45]. Alcoholic fatty liver disease can 
also cause steatosis and steatohepatitis by reducing β-oxidation, increasing fatty acid 
synthesis, and reducing fatty acid clearance [46]. Although cases are rare, drug-induced 
fatty liver can happen in various ways depending on the drug. Drugs can cause 
microvesicular steatosis by reducing β-oxidation, macrovesicular steatosis through 
triglyceride accumulation, and drug-induced steatohepatitis by increasing reactive oxygen 
species content [47]. 
Steatosis and steatohepatitis are often asymptomatic and can be reversed if the 
damaging agent is eliminated. More recent studies indicate that fibrosis can also be 
reversed through the removal of harmful stimuli. However, when damaging stimuli 
persist, inflammation and fibrosis can lead to a worsening of liver disease. Fibrosis is 
initially triggered by the amassing of inflammatory cells to the liver. These inflammatory 
cells produce chemokines, including transforming growth factor-beta (TGF-β), platelet-
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derived growth factor (PDGF), and tumor necrosis factor-alpha (TNF-α), that activate 
quiescent hepatic stellate cells [48, 49], which synthesize and secrete extracellular matrix 
proteins such as collagen 1a1 (Col1a1) and alpha-smooth muscle actin (α-SMA) [50]. 
These components contribute to the build-up of fibrotic tissue in the liver. Continued 
accumulation of fibrous materials can lead to cirrhosis. Liver cirrhosis, also known as 
end-stage liver disease, is not reversible and results in an increased amount of damage 
that disrupts the liver’s normal functioning [51]. Cirrhosis is life-threatening, and 
although certain drugs can reduce the progression of cirrhosis, the only real treatment is a 
liver transplant. 
The inflammatory environment of the cirrhotic liver promotes the development of 
transformed cells that can lead to cancer. Liver cancer is one of the leading causes of 
cancer deaths in the world [52, 53]. Although viral causes of liver cancer are decreasing, 
cases associated with NAFLD are dramatically increasing. Hepatocellular carcinoma 
(HCC) is a malignancy of the hepatocyte that comprises the most significant amount of 
liver cancer cases [54]. Other lesser occurring instances include cancers of 
cholangiocytes (cholangiocarcinoma) and blood vessels, but those result in far fewer 
cases per year. Cancer of the liver and bile duct rank as the 5th highest cancer death in 
American men and 7th in American women in 2021 [55], and liver cancer is projected to 
be the second leading cause of cancer deaths by 2030 [56]. 
The liver is unique among internal organs in that it has the remarkable ability to 
regenerate after damage. In times of damage, the liver activates signaling pathways to 
restore liver mass. The healthy liver is relatively quiescent, and there is a low level of 
hepatocyte loss and renewal. However, hepatocytes can replenish themselves by 
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activating signaling systems required for cellular regeneration via the re-entry of 
hepatocytes into the cell cycle when there is significant cell loss. In a rodent partial 
hepatectomy model, in which 70% of the liver is surgically removed, hepatocytes activate 
signaling molecules essential for hepatocyte proliferation, including Notch 1 and 
epidermal growth factors (EGF), within an hour [57, 58]. Following hepatocyte 
proliferation, the hepatocyte produces growth factors that stimulate angiogenesis and 
proliferation of other resident cells of the liver [59]. As a result, the liver can regenerate 
to its normal mass in response to the loss of liver cells within 7-10 days. 
The liver can also regenerate in response to other models of liver injury, including 
those caused by hepatotoxins such as CCl4. These types of liver damage are often zonal 
due to the zonal expression of liver enzymes and usually requiring a different 
regeneration response than partial hepatectomy. In most liver diseases or after any 
hepatocyte damage, regeneration is required. Initially, after damage, the remaining 
hepatocytes must receive signals to initiate their re-entry into the cell cycle. Priming the 
hepatocytes initializes this proliferation, which results in increased c-jun and c-myc 
signaling and production of the inflammatory cytokines TNF-α and interleukin-6 (IL-6) 
[60, 61]. This cascade of events enables the transition of quiescent hepatocytes to 
proliferative hepatocytes. After the initial priming phase, growth factors, including 
hepatocyte growth factor (HGF) and endothelial growth factor (EGF), are released, 
causing hepatocytes to enter the cell cycle [62, 63]. Hepatocytes can regenerate to replace 
damaged or apoptotic cells and then undergo the termination phase once the liver regains 
its normal size. Although there are many unknowns regarding the termination of 
hepatocyte regeneration, TGF-β signaling has a role in stopping hepatocyte proliferation 
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[64]. Through this multi-phased process, the liver can orchestrate the regeneration and 
repair of lost hepatocytes so that the liver can maintain metabolic functions when 
regaining normal liver size. 
1.4 Models of Liver Disease 
Animal models of liver disease have helped to elucidate disease mechanisms and 
potential therapeutic treatments, although many experimental models do not fully 
recapitulate liver disease in humans. Mouse models for NAFLD focus on either a 
genetics-based or a diet-based approach [65]. Alcohol liver disease (ALD) requires the 
administration of ethanol orally or through intragastric infusion [66]. One of the most 
commonly used liver fibrosis models requires administering the hepatotoxin CCl4. As 
noted previously, the metabolism of CCl4 by hepatic Cyp2e1 produces free radicals 
causing significant damage and death of hepatocytes. A single dose of CCl4 leads to 
transient damage, whereas ongoing treatment over six weeks leads to continual damage 
and regeneration and activation of stellate cells, ultimately resulting in fibrosis [67]. 
Another commonly used fibrosis model is bile duct ligation, a surgical method of liver 
damage and fibrosis caused by accumulating bile acids within the liver; an attractive 
aspect of this model is that it often mimics human liver disease [68]. Alternatively, diets 
used for NAFLD models like Methionine Choline Deficient diet (MCD) and high-fat 
(HF) diets can also cause liver damage, including fibrosis [69]. DEN is often used as a 
model for HCC, causing DNA damage that results in tumor development [13]. There is 
considerable debate in the liver field regarding different animal models and their ability 
to fully recapitulate all aspects of liver disease progression in humans. 
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1.5 Inbred mouse strains 
Mice have been bred for interesting behavioral characteristics and coat colors for 
thousands of years [70]. More recently, mice have been bred for phenotypic traits that can 
be of use in biomedical research for studying human disease [70]. Through thousands of 
years of breeding, many strains and substrains have been developed which can possess 
unique characteristics [71] (Figure 1.2). One commonly studied difference between 
substrains is the difference between C57BL/6J and C57BL/6N mice. When the 
sequencing of these two mice was compared, 34 single nucleotide polymorphisms and 15 
structural variants were identified [72]. C57BL/6J mice have a mutation in the 
nicotinamide nucleotide transhydronase, which has been found to contribute to impaired 
glucose tolerance and insulin secretion [73]. Research characterizing unique phenotypes 
between mouse strains can be used as a tool to identify genes that could be involved in 
disease. 
1.6 Alpha-fetoprotein (AFP) 
Alpha-fetoprotein (AFP) is a serum transport protein produced by hepatocytes in 
the developing fetal liver; in fact, AFP is the earliest known marker of hepatocytes as 
they differentiate from the foregut endoderm during development. AFP is highly similar 
in both structure and function to albumin, which is also expressed in the liver and is the 
major serum transport protein in adult mammals [53]. Comparisons of albumin and AFP 
genes indicate that they are evolutionarily related and have the same structure as other 
members of this gene family, which also includes alpha-albumin, Alpha-fetoprotein 
related gene, and vitamin D binding protein [74]. In addition to the fetal liver, AFP is 
expressed in the yolk sac and, to a lesser extent, in the lower gastrointestinal tract levels 
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[75]. AFP is the most abundant protein synthesized in the fetal liver, but its expression 
drops off dramatically within the first several weeks after birth [76]. AFP levels typically 
remain low in the healthy adult liver, but AFP expression transiently increases in the 
regenerating liver after liver damage and is often reactivated in liver cancer, including 
HCC. AFP serum levels often correlate with liver disease and HCC severity enabling the 
use of serum AFP as an important biomarker. [77]. In most models of toxic liver injury 
that requires hepatocyte regeneration, AFP levels were found to significantly increase 
[78]. In human cell culture lines, more significant cell proliferation and growth are 
associated with increased AFP expression [79]. Furthermore, poorer HCC prognosis and 
an increased chance of reoccurrence correlated with higher AFP levels [80]. Studies 
investigating AFP expression in the liver have found different mouse strains that have 
traits of AFP expression during development and disease, as described further below.  
1.7 Alpha-fetoprotein regulator 1 (Afr1)/Zinc fingers and homeoboxes 2 (Zhx2/Afr1) 
Due to high AFP levels in HCC, Olsson et al. analyzed serum AFP levels in 27 
different strains of inbred mice; this study found that adult BALB/cJ mice had 
significantly higher AFP serum levels than all other mouse strains studies, including 
several other BALB/c substrains [81]. The elevated AFP levels in the postnatal liver of 
BALB/cJ mice were due to a recessive, monogenic trait, and the locus that controlled this 
trait was called in called alpha-fetoprotein regulator 1 (Afr1) [81]. After Tilghman and 
colleagues cloned the AFP gene, they showed increased liver AFP mRNA levels 
correlated with increased serum AFP [82]. Blankenhorn et al. found that the Afr1 locus 
was located on mouse Chromosome 15 close to the c-Myc gene [83]. Our lab further 
localized Afr1 to a small region of Chromosome 15, and analysis of genes in this region 
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found that a hypomorphic mutation in BALB/cJ Zinc fingers and homeoboxes 2 (Zhx2) 
gene was responsible for the Afr1 trait [84, 85]. The Zhx2 protein contains two zinc 
fingers and four homeodomains, suggesting that it functions as a transcription factor. This 
led us to propose that Zhx2 contributes to postnatal silencing of the AFP gene, and the 
Zhx2 mutation in BALB/cJ mice results in incomplete AFP repression [84]. In addition to 
AFP, Zhx2 represses the expression of other fetal liver genes that are often reactivated in 
liver disease and HCC, including Glypican 3 (Gpc3) and the long noncoding RNA 
(lncRNA) H19 [84, 86]. 
Zhx2 mutation serves as a possible candidate for several phenotypic traits that are 
seen in BALB/cJ mice (Figure 1.3). The lab of Jake Lusis found that BALB/cJ mice, 
when given a high-fat diet, had fewer atherosclerotic plaques than other mouse strains 
[87]. This trait, named Hyperlipidemia 2 (Hyplip 2), was mapped by quantitative trait 
locus QTL analysis to a region of chromosome 15 where Zhx2 is located. In a 
collaboration between our lab and the Lusis lab, it was found that the Zhx2 mutation in 
BALB/cJ mice was responsible for the Hyplip2 phenotype [88]. Our lab determined that 
BALB/cJ mice, when given a high-fat diet, showed higher lipid content in the liver and 
increased inflammation compared to mice with a wild-type Zhx2 gene [89]. These 
findings indicate that Zhx2 controls the developmental expression of target genes as well 
cardiovascular disease and diet-induced liver injury. 
In the chronic CCl4 liver fibrosis model, BALB/cJ mice were found to have 
greater liver damage, as judged by fibrotic injury, than other mouse strains [90, 91]. 
Using QTL analysis, this study concluded that the fibrosis phenotype was associated with 
several hepatic fibrosis (Hfib) loci. The most significant QTL, called Hfib1, was 
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localized to the same region of chromosome 15 as Zhx2. Since our lab showed that the 
Zhx2 gene is mutated in BALB/cJ mice, this led us to hypothesize that Zhx2 is 
responsible for the Hfib1 trait and serves as a potential candidate for the increased 
fibrosis seen in BALB/cJ mice. 
1.8 Alpha-fetoprotein regulator 2 (Afr2) 
In an early study of liver regeneration using CCl4, it was found that C3H/HeJ 
mice had significantly higher increased AFP expression compared to C57BL/6J [82]. 
This difference in AFP activation was a monogenic trait governed by a locus called 
alpha-fetoprotein regulator 2 (Afr2). The Afr2a allele in C3H/HeJ mice was dominant 
over the Afr2b allele found in C57BL/6J mice. Curiously, other genes that are targets of 
Zhx2, including H19 and Gpc3, also appear to be regulated by Afr2. The Afr2 locus was 
mapped to a region on mouse chromosome 2 [92], although it should be noted that this 
study, in contrast to earlier studies, suggested that the Afr2a and Afr2b alleles were co-
dominant. Several candidate genes for Afr2 fall within this region of Chromosome 2 





Figure 1.1 Liver Structure and Function. 
(A). Layout of the liver lobule with six portal triads surrounding a single central vein. 
Hepatocytes in the lobule are located in zone 1 (periportal region), zone 2, or zone 3 
(pericentral region (B). Labeled image of how the liver lobule works, with blood flowing 
from portal vein/hepatic artery, past the major cells of the liver, to the central vein; bile 













Figure 1.2 Phylogenetic tree of inbred mouse strains.  
Figure from Petkov PM, Ding Y, Cassell MA, Zhang W, Wagner G, Sargent EE, Asquith 
S, Crew V, Johnson KA, Robinson P, Scott VE, Wiles MV. An efficient SNP system for 
mouse genome scanning and elucidating strain relationships. Genome Res. 2004 





Figure 1.3 The Zhx2 gene co-localizes with several traits that are seen in BALB/cJ 
mice.  
Quantitative trait analysis (QTL) mapping of the Zhx2/Afr1 interval responsible for 
increased AFP levels in BALB/cJ mice to a region on mouse chromosome 15 (green). 
Other phenotypic traits, including Hyplip2 (Blue), Hfib1 (Orange), and Male aggression 













Figure 1.4 Mapping of Afr2 interval on chromosome 2. 
Quantitative trait analysis (QTL) mapping of the Afr2 interval responsible for differing 
AFP reactivation responses in liver regeneration in C3H/HeJ and C57BL/6J mice to a 















CHAPTER 2. MATERIALS AND METHODS 
2.1 Mice 
 Mice were housed in the University of Kentucky Division of Laboratory Animal 
Research (DLAR) facility and were kept according to approved Institutional Animal Care 
and Use Committee (IACUC) protocols. Mice were purchased from The Jackson 
Laboratory, obtained from the Knockout Mouse Project (KOMP), or bred in-house. The 
mice were maintained on a 14/10 light/dark cycle and had access to ad libitum food and 
water. 
2.2 Generating BALBcJAfr1/Afr1 and BALBcJWT/Afr1 mice 
 Male BALB/cJ mice, homozygous for the Zhx2Afr1 allele, were bred to female 
BALB/cByJ mice that were homozygous for wildtype Zhx2 allele (Zhx2WT). Female 
offspring of this mating (BALB/cJWT/Afr1) were backcrossed to male BALB/cJ mice to 
obtain male and female BALB/cJAfr1/Afr1 and BALB/cJWT /Afr1 F2 offspring. At 8-weeks of 
age, F2 mice were administered carbon tetrachloride (CCl4) injections as described below. 
2.3 Generating Zhx2WT/Afr1 and Zhx2KO/Afr1 mice 
 Zhx2Fl/Fl mice were initially purchased from the Knockout Mouse Project 
Repository (KOMP) at the University of California- Davis. These mice had loxP sites 
flanking Zhx2 exon 3, which contains the entire Zhx2 protein-coding region. When exon 
three was deleted, it resulted in a complete deletion of the Zhx2 protein. Male BALB/cJ 
mice (BALB/cJAfr1) were bred to C57BL/6 mice heterozygous for the null mutation in the 
Zhx2 gene (Zhx2WT/KO) to obtain male and female Zhx2WT/Afr1 and Zhx2KO/Afr1 offspring. 
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Mice were maintained until 8-weeks of age before starting CCl4 injections as described 
below. 
2.4 Afr2 Pilot Study 
 Male mice from six strains: 129X1/SvJ, C3H/HeJ, DBA/2J, C57BL/6J, 
C57BL/6NJ, and C57BL/10SnJ were obtained from the Jackson Laboratory and used to 
determine AFP activation during liver regeneration. Mice were maintained until 6-weeks 
of age before receiving a single dose of CCl4 or mineral oil (MO), as described below. 
2.5 Generating 129x1SvJxBL/6J 
 Breeding pairs of 129X1/SvJ and C57BL/6J mice were set up to generate male 
and female F1 offspring. Mice were maintained until 8-weeks of age before receiving a 
CCl4 or MO injection. 
2.6 Genotyping 
 When pups were approximately 14 days of age, mice were ear-tagged for 
experimental identification, and the removed ear skin was digested overnight at 55°C in 
500 µL of tail lysis buffer (100 mM Tris-HCl pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM 
NaCl, 100 µg/mL Proteinase K). After digestion, samples were briefly vortexed, 500 µL 
of isopropanol was added, and samples were thoroughly mixed to precipitate the DNA. 
The DNA was pelleted by centrifugation at 13,000 g for 5 minutes, and the supernatant 
was decanted. The pellet was then washed with 500 µL of 75% EtOH and centrifuged at 
13,000 g for 5 minutes, and the supernatant was again decanted. Tubes were inverted on a 
paper towel to dry for 30 minutes. Pellets were resuspended in 100 µL sterile ddH2O. For 
BALB/cJ genotyping, 2 µL of DNA was added to a PCR mixture including 10 µL 2x 
20 
 
Dream Taq (Thermo Scientific), 7.4 µL of ddH2O, 0.3 µL of the forward primer, and 0.3 
µL of the reverse primer. Three PCR reactions were used to determine BALB/cJ 
genotyping by pairing primers for Afr1 and ETn3Flank to determine BALB/cJWT (no 
product for BALB/cJAfr1, amplicon 392 bp for BALB/cJWT), Afr1, and Afr2 to determine 
BALB/cJAfr1 (amplicon 269 bp for BALB/cJAfr1, no product for BALB/cJWT), and 
ETn3Flank and Afr3 to determine BALB/cJAfr1 (amplicon 786 bp for BALB/cJAfr1, no 
product for BALB/cJWT). For Zhx2 genotyping, 2 µl of DNA was added to a PCR 
mixture, including 10 µL of 2x Dream Taq (Thermo Scientific), 0.3 µL of Zhx25F 
primer, 0.3 µL of LAR3 primer, and 0.3 µL Zhx25R primer, and 7.1 µL water. The 
amplicons for Zhx2 genotyping will be 230 bp for the Zhx2 floxed allele (Zhx2KO) and 
385 bp for the wild-type Zhx2 allele (Zhx2WT). Samples for BALB/cJ and Zhx2 
genotyping underwent the same PCR protocol: 95°C for 3 minutes, 40 cycles of 95°C for 
30 seconds, 55°C for 30 seconds, and 72°C for 40 seconds, and a final 72°C for 5 
minutes. Primer sequences are listed in Table 2.1. The resulting product was mixed with 
5 µL of 6x loading dye, and 10 µl was loaded on a 1% agarose gel along with 3ul of 
Gene Ruler 100bp Plus (Thermo Scientific). Samples were run at 150V for 30 minutes 
and visualized using an Amersham Imager 600 (GE). 
2.7 Model for liver fibrosis (CCl4) 
 At eight weeks of age, mice were selected to be injected intraperitoneally with 0.5 
mL/kg of carbon tetrachloride (CCl4) that was diluted 1:10 in mineral oil; control mice 
received mineral oil (MO) alone, prepared weekly. Each injection was performed with a 
28G insulin syringe (Becton Dickinson). Mice were injected twice weekly for a total of 6 
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weeks (12 injections). Forty-eight hours after the final injection, at 7:00 AM, unfasted 
mice were euthanized. 
2.8 Model for acute liver damage and regeneration (CCl4) 
 When mice were at 6 or 8 weeks of age, mice were injected intraperitoneally with 
50 µL of a solution containing 2.5mg/kg CCl4 dissolved in MO or MO alone, as 
described above. Seventy-two hours after injection, at 10:00 AM, unfasted mice were 
euthanized. 
2.9 Euthanasia and Tissue Collection 
 At the end of each animal study, individual mice were weighed and euthanized in 
a CO2 chamber (30-70% cage volume/minute), followed by cervical dislocation. Blood 
was collected by cardiac puncture using a 1mL syringe with a 26G needle and allowed to 
clot for approximately one hour. Serum was obtained by centrifuging the blood sample at 
13,000g for 3 minutes, and the clear supernatant was transferred to a new tube. The 
mouse liver was excised from the abdominal cavity, weighed, and cut into smaller 
sections. Sections were selected and placed in a cassette and placed in formalin for 3 
days. After 3 days, cassettes were briefly washed in ddH2O and stored in 70% ethanol 
until being paraffin-embedded. Liver sections were also frozen at -80°C in OCT for 
sectioning or frozen at -80°C in tubes for RNA and DNA extraction. 
2.10 RNA extraction/cDNA/qPCR 
 Frozen liver sections that were stored at -80°C were weighed before RNA 
extraction. Tissue samples (~50 mg) were homogenized using a pestle in 200 µl RNAzol 
(Molecular Research Center Inc.). An additional 800 µL of RNAzol was added and 
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pipetted to mix. Sterile ddH2O (400 µL) was added to the mixture, which was then mixed 
vigorously for 15 seconds. After incubation at room temperature for 15 minutes, the 
samples were centrifuged at 13,000 g for 15 minutes at 4°C. After centrifuging, the 
sample tubes contained clear supernatant and a dark pellet. Careful to not disturb the 
pellet, the supernatant (1.2 mL) was transferred to two tubes (600 µL/tube), followed by 
the addition of equal parts of isopropanol. The solution was mixed and stored at 4°C for 
approximately 1 hour, followed by centrifugation at 13,000 g for 10 minutes, and the 
supernatant was decanted. The resulting pellet was washed twice with 75% ethanol, 
centrifuged at 8,000 g for 5 minutes, and decanting ethanol in between washes. The pellet 
was dried for approximately 15-30 minutes, and the RNA pellet was dissolved in sterile 
100 to 200 µL of ddH2O. RNA concentrations were determined using a Nanodrop 
(Thermo Scientific). An aliquot of RNA was added to sterile ddH2O to obtain a final 
RNA concentration of 1 ug/10µl of ddH2O. RNA was converted into cDNA using High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). RNA (1 µg/10µL) was 
combined with 2 µL of 10x buffer, 2 µl of random primers, 0.8 µL dNTPs, 1 µL of 
reverse transcriptase, and 4.2 µL of ddH2O. The mixture was placed into 0.2 mL PCR 
tubes and subjected to the following PCR using a SimpliAmp Thermal Cycler (Applied 
Biosystems): 25°C for 10 minutes, 37°C for 2 hours, 85°C for 5 minutes. Quantitative 
Real-Time PCR (qPCR) assays were conducted using the following reagents: 10 µL of 
SYBR Green PCR Supermix (Bio-Rad), 0.5 µL of 10 µM forward and reverse primers, 8 
µL sterile ddH2O, and 1 µL cDNA. qPCR was conducted using the CFX96 Real-Time 
System (Bio-Rad) and was subjected for the following PCR: 95°C for 3 minutes, 40 
cycles of 95°C for 10 seconds and 60°C for 45 seconds, followed by a melt curve, and 
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analyzed using the CFX Manager software (Bio-Rad). Oligonucleotide primer sequences 
are listed in Table 2.2. Transcript CT values were normalized to serine/arginine-rich 
splicing factor 4 (SFRS4), a splicing factor and housekeeping gene, and analyzed using 
the ΔΔCT method [93]. SFRS4 has been found to be a more consistently expressed 
housekeeping gene compared to GAPDH in advanced liver diseases like HCC [94]. 
2.11 Histology 
 All histology was performed by the COBRE Pathology Research core or the 
Markey Cancer Center Biospecimen Procurement and Translational Pathology Shared 
Resource Facility. Formalin-fixed tissue samples were paraffin-embedded. Paraffin-
embedded blocks were cut at 6-micron thickness on a microtome. Sections were adhered 
to slides and stained for Hematoxylin and Eosin, Sirius Red, or Masson Trichrome. Sirius 
Red was used for staining collagen and amyloid [95] and Masson Trichrome stains type I 
collagen [96]. Sirius red staining has been shown to have red fluorescence [97]. Sirius 
Red was quantified by using fluorescent microscopy and analyzed on ImageJ using mean 
fluorescence measurement. 
2.12 TGF-β ELISA 
 Serum TGF-β levels were determined using the R&D Systems Quantikine ELISA 
TGF-β kit (DB100B) per the manufacturer’s instructions. Serum samples were first 
activated by adding 40 µL of serum to a polypropylene tube along with 20 µL of 1N 
HCL. The sample was mixed and incubated for 10 minutes at room temperature. Samples 
were then neutralized by adding 20 µL of 1.2 N NaOH/0.5 M HEPES and mixed. After 
neutralization, the samples were further diluted with calibrator diluent: 40-fold dilution 
for mineral oil samples (5 µL in 195 µL) or 80-fold dilution for CCl4 samples (2.5 µL in 
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197.5 µL). The ELISA plate was loaded with 50 µL of assay diluent and 50 µL of 
standard, controls, and activated samples. The plate was gently mixed, covered, and 
incubated at room temperature for two hours. After incubation, the ELISA plate was 
aspirated and washed four times with wash buffer, blotting on paper towels in between. 
After washing, 100 µL of TGF-β conjugate was added to each well, covered, and 
incubated for two hours at room temperature. The plates were then washed four times 
with wash buffer, blotting on paper towels in between. After the plate was blotted dry, 
100 µL of the substrate solution was added, and the plate was protected from light for 30 
minutes for color development. One hundred microliters of stop solution were added to 
each well to block further color development, and the optical density was measured at 
450 nm and 560 nm as wavelength correction. The concentrations were calculated based 
on the standard curve and then multiplied by their dilution factor. 
2.13 ALT Assay 
 Serum Alanine Aminotransferase (ALT) levels were assessed using an Alanine 
Aminotransferase Activity Kit (Sigma Aldrich) per the manufacturer’s instructions. 
Samples were prepared by diluting 10 µL of MO-treated serum samples in 10 µL of ALT 
Assay Buffer or 5 µL of CCl4-treated serum samples in 15 µL of ALT Assay Buffer into 
a 96-well microplate. This was followed by the addition of 100 µL of master reaction mix 
(86 µL ALT Assay Buffer, 2 µL Fluorescent Peroxidase Substrate, 2 µL ALT Enzyme 
Mix, 10 µL ALT Substrate). Samples were protected from light and incubated at room 
temperature for 3 minutes, followed by an initial reading at 560 nm. Samples were then 
incubated at 37°C and read again after 2, 5, 8, and 10 minutes. The final reading is the 
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last reading in which none of the samples exceed the standard curve. Calculations to 
determine ALT levels were performed as per the manufacturer’s instructions. 
2.14 AFP ELISA 
 Alpha-fetoprotein (AFP) serum levels were measured using the R&D Systems 
Quantikine ELISA Alpha-fetoprotein/AFP kit (MAFP00) according to the manufacturer’s 
instructions. Serum samples were diluted 200-fold in calibrator diluent before use in the 
ELISA. Fifty microliters of assay diluent were added to the plate along with 50 µL of 
standard or diluted sample. The plate was covered and incubated at room temperature for 
2 hours on a horizontal orbital microplate shaker at 500 rpm. After incubation, wells were 
aspirated and washed four times with wash buffer, blotting dry on paper towels between 
each wash. After the final blotting, 100 µL of Mouse AFP conjugate was added, and the 
plate was incubated for 2 hours at room temperature on the horizontal orbital microplate 
shaker. The plate was then aspirated and washed four times with wash buffer, blotting dry 
on paper towels between each wash. Next, 100 µL of substrate solution was added, and 
the plate was protected from light for 30 minutes as the color developed. To stop color 
development, 100 µL of stop solution was added to each well, and the optical density was 
read at 450nm and 560nm for wavelength correction. The concentrations were calculated 
based on the standard curve and multiplied by 200 to determine AFP levels in the 
undiluted serum samples. 
2.15 Hydroxyproline 
 Hydroxyproline assays were conducted using the Hydroxyproline Colorimetric 
Assay Kit (BioVision). Samples were prepared by homogenizing 10mg of frozen liver 
tissue in 100 µL of ddH2O. Tissue homogenate (~100 µL) was added to a glass tube with 
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a Teflon-lined cap, and 100 µL of concentrated HCl (12N) was added. The samples were 
hydrolyzed for 3 hours at 120°C. After hydrolysis, 40 µL of sample and the standard per 
manufacturer’s instructions was added to a transparent flat-bottomed 96-well plate and 
dried in a 60°C oven for approximately 1 hour. While drying, hydroxyproline kit reagents 
were warmed to room temperature, and both the Chloramine T reagent and DMAB 
Reagent were prepared per the manufacturer’s instructions. Chloramine T reagent (100 
µL) was added to each standard and sample well and incubated at room temperature for 5 
minutes. DMAB reagent (100 µL) was then added to each well. The plate was covered 
and incubated at 60°C for 1.5 hours. The plate was read on the GloMax Microplate reader 
(Promega) at 560 nm. The concentration was determined using the standard curve and 
calculated using the manufacturer’s instructions. 
2.16 Statistics 
 All data is represented as a mean +/- standard deviation. Descriptive statistics and 
Normality tests were performed on each data set using GraphPad Prism 9. A two-tailed t-
test or one-way ANOVA with multiple comparisons of means was calculated using 
GraphPad Prism 9 when appropriate. Post-hoc tests were selected based on the 
distribution of the data. A p-value of less than 0.05 was considered significant. Outliers 
were detected using Grubbs’ test using GraphPad Prism outlier calculator and not 






Figure 2.1 Breeding schematic for the Hfib1 project. 
BALB/cJ mice that were homozygous for the Afr1 mutation were bred to F1 mice 
(BALB/cJAfr1/Afr1x BALB/cByJWT/WT) to obtain male and female mice that express 
normal Zhx2 levels (BALBcJWT/Afr1) and low Zhx2 levels (BALB/cJAfr1/Afr1) (A). 
BALB/cJ mice that were homozygous for the Afr1 mutation were bred to heterozygous 
Zhx2WT/KO on a C57BL/6J background to obtain male and female mice that express 











Figure 2.2 Experimental design for the Hfib1 study. 
Mice selected for the Hfib1 experiment were maintained for 8 weeks until the start of the 
injection series. Mice were then given either mineral oil or CCl4 twice weekly for 6 weeks. 
Forty-eight hours after the last injection, mice were euthanized, and tissues were collected. 






















Figure 2.3 Experimental design for Afr2 pilot study. 
Male mice from six mouse strains (129X1/SvJ, C3H/HeJ, DBA/2J, C57BL/10SnJ, 
C57BL/6NJ, and C57BL/6J) were injected once with either mineral oil or CCl4. After 72 


















Figure 2.4 Experimental design for Afr2 full liver regeneration study. 
129X1/SvJ, C57BL/6J, and F1 male and female mice were injected once with either 
mineral oil or CCl4. After 72 hours, mice were euthanized, and tissue was collected. 










































































































CHAPTER 3.  THE INCREASED FIBROSIS PHENOTYPE, HFIB1, IN BALB/CJ 
MICE IS NOT DUE TO THE MUTATION IN ZHX2 (AFR1) 
3.1  Introduction 
Liver disease prevalence has a significant clinical impact, being the cause of two 
million deaths globally in 2010, with one million of those being due to liver cirrhosis 
[98]. Liver fibrosis and cirrhosis occur when harmful stimuli cause persistent damage, 
resulting in the production of extracellular matrix proteins. Fibrotic accumulation within 
the liver is initially triggered by hepatocyte damage. Studies have shown that in the case 
of lipotoxic injury, hepatocytes increase the release of vesicles that contains tumor 
necrosis factor apoptosis ligand (TRAIL), which activates macrophages [99]. These 
inflammatory cells then produce and release chemokines, including TGF-β, PDGF, and 
TNF-α [48, 49]. These chemokines bind to specific receptors on hepatic stellate cells to 
cause activation and promote the transition to myofibroblasts [100]. The activated 
extracellular matrix cells produce collagen 1a1 and α-SMA, contributing to the build-up 
of fibrosis in the liver [50]. As fibrotic tissue continues to accumulate in the liver, the 
organ may become cirrhotic, resulting in an increased amount of irreparable damage that 
disrupts the liver’s normal functioning [51]. 
One specific mouse substrain, BALB/cJ, has been found to display several unique 
phenotypic traits. BALB/cJ mice exhibit persistent expression of fetal liver genes into 
adulthood [82, 84]. This trait is due to a hypomorphic mutation in the gene Zinc fingers 
and homeoboxes 2 (Zhx2), located on chromosome 15, leading to significantly lower 
Zhx2 protein levels [82, 84]. BALB/cJ mice also display reduced atherosclerotic plaques 
than other mouse strains when fed a high-fat diet [87]. QTL analysis determined that this 
34 
 
trait, named Hyperlipidemia2 (Hyplip2), mapped to the same region on chromosome 15 
as Zhx2. Further research using Zhx2 transgenic BALB/cJ mice determined that the Zhx2 
mutation was responsible for the reduced atherosclerotic phenotype in BALB/cJ mice 
[88]. Although there were reductions in cardiovascular disease using the high-fat diet 
model, studies in our lab demonstrated that there was increased liver pathophysiology, 
including increased lipid accumulation and inflammation, in BALB/cJ mice fed a high-fat 
diet; this liver phenotype is due to the Zhx2 mutation [89]. Other traits in BALB/cJ mice, 
including altered expression of numerous Cyp and Major urinary proteins (Mup) genes, 
are due to the Zhx2 mutation in this strain [101, 102]. 
A screen for differences in liver fibrosis in a panel of mouse strains indicated that 
BALB/cJ mice exhibit increased liver fibrosis in a chemical-induced model of chronic 
liver damage. In this CCl4 model, BALB/cJ mice were shown to have increased fibrotic 
histology and hydroxyproline levels compared to A/J and FVB/N mice [90, 91]. These 
studies found that when BALB/cJ mice were crossed with these other strains, the 
offspring had reduced fibrosis, indicative of a recessive mutation. QTL analysis revealed 
several loci that controlled increased fibrosis in BALB/cJ mice. The strongest of these 
QTLs, named Hepatic fibrosis 1 (Hfib1), mapped to the same region of chromosome 15 
as Zhx2.  
Although the Hfib1 region overlaps with Zhx2, the gene responsible for Hfib1 is 
unknown. Considering both the overlap of the Hfib1 interval with Zhx2 and the effect 
Zhx2 has on several liver phenotypes in BALB/cJ mice, we hypothesize that the Zhx2 
mutation is responsible for the Hfib1 fibrosis phenotype in this mouse strain. To directly 
test this, I performed two complementation experiments using the chronic CCl4-treated 
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liver fibrosis model. Although we hypothesized that there would be a difference in 
fibrosis markers between mice that did or did not express Zhx2, we observed no 
significant differences in fibrosis. This finding eliminates Zhx2 as a candidate Hfib1 gene 
and suggests that there is another gene in this region responsible for the increased fibrosis 
phenotype. 
3.2 Results 
As described in chapter 2, our lab obtained mice with a floxed allele of the Zhx2 
gene from the KOMP. We have crossed this allele to C57BL/6J and to mice with the 
actin-Cre transgene to delete Zhx2 exon 3 in all cells; the deleted allele will be referred 
to as Zhx2KO.  
Two complementation studies were performed. First, BALB/cJ mice 
(BALB/cJAfr1/Afr1) were bred to Zhx2WT/KO mice to generate offspring that were 
Zhx2Afr1/WT or Zhx2Afr1/KO. We also bred BALB/cJ mice to BALB/cByJ, which is highly 
related to BALB/cJ but has a wild-type Zhx2 gene to obtain an F1. These F1 offspring 
were backcrossed to BALB/cJ to obtain F2 offspring that were BALB/cJAfr1/WT or 
BALB/cJAfr1/Afr1. PCR of genomic DNA was used to confirm the Zhx2 alleles in 
experimental animals. At 8 weeks of age, mice from each genotype received either MO 
or CCl4 twice weekly for 6 weeks. Forty-eight hours after the final injection, livers and 
serum were collected. Analysis of liver RNA in both studies confirmed that Zhx2 mRNA 
levels in both male and female Zhx2KO/Afr1 and BALB/cJAfr1/Afr1 mice were dramatically 
lower than Zhx2 levels in Zhx2WT/Afr1 and BALB/cJWT/Afr1 littermates (Fig. 3.1 A-D). 
Zhx2 expression in male and female mice from both cohorts did not significantly change 
due to CCl4 treatment (Fig. 3.1A-D). 
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 With confirmation that Zhx2 expression was reduced in these mice as expected, 
liver damage was assessed using histological staining. The overall liver damage and 
fibrosis observed in CCl4-treated mice was assessed using hematoxylin & eosin, Masson 
trichrome, and Sirius red staining (Fig. 3.2 A-D). Although it was seen that CCl4-treated 
mice displayed increased liver damage and fibrosis, histological results show that 
differences in Zhx2 expression did not alter the fibrosis levels, as determined 
histologically, when mice were treated chronically with CCl4 (Fig. 3.2 A-D). Initial 
quantification of Sirius Red staining revealed no significant difference in average 
fluorescence except female Zhx2KO/Afr1 when compared to Zhx2WT/Afr1 treated with CCl4 
(Figure 3.3 A-D). These results will further need to be confirmed by a pathologist and 
quantified using fluorescent microscopy.  
 In addition to histological assessment, mRNA expression levels of fibrosis 
markers associated with fibrosis were also analyzed. Alpha smooth muscle actin (Gene: 
ACTA2) mRNA expression levels were found to be substantially higher in CCl4-treated 
compared to MO-treated mice in male and female mice of both cohorts (Fig. 3.4 A-D). A 
similar pattern was observed when Collagen1a1 mRNA levels were analyzed; levels 
increased in both male and female CCl4-treated mice compared to MO controls but were 
not affected by Zhx2 levels (Fig 3.5. A-D). Timp1, which regulates matrix 
metalloproteinases, was also analyzed. Timp1 mRNA levels also increased in CCl4-
treated mice but were not affected by Zhx2 levels (Fig. 3.6 A-D). Hydroxyproline is a 
major component of collagen and can be used to measure collagen levels [103]. In 
previous studies identifying the Hfib1 region, hydroxyproline has been used as a marker 
of fibrosis [90]. Hydroxyproline levels were also assessed in these experimental mice 
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using a colorimetric kit, showing no significant changes regardless of treatment or Zhx2 
expression (Figure 3.7).  
 Increased inflammation is a hallmark of liver disease, including liver fibrosis. We, 
therefore looked at several inflammatory cytokines in these experimental mice. Levels of 
Tumor Necrosis Factor α (TNFα) and Transforming Growth Factor-β (TGF-β) were 
assessed in all groups. In Zhx2WT/Afr1 and Zhx2KO/Afr1 mice, TNFα mRNA levels only 
differed between Zhx2KO/Afr1 CCl4 and MO-treated male mice (Fig. 3.8 A-B). In 
BALB/cJWT/Afr1 and BALB/cJAfr1/Afr1 mice, there were no significant changes in TNFα 
expression regardless of treatment or sex (Fig. 3.8 C-D). However, TGF-β mRNA levels 
were higher in the male and female Zhx2WT/Afr1, Zhx2KO/Afr1, BALB/cJWT/Afr1, and 
BALB/cJAfr1/Afr1 mice treated with CCl4 than MO-treated mice, but only significantly in 
male and female Zhx2WT/Afr1, male Zhx2KO/Afr1, and male BALB/cJAfr1/Afr1 (Fig. 3.9 A-D). 
Zhx2 expression did not significantly change TGF-β mRNA levels. Serum levels of TGF-
β were assessed using ELISA. Regardless of treatment or Zhx2 expression, TGF-β levels 
did not significantly differ for all mice (Fig. 3.10 A-D). 
 In addition to assessing fibrosis and inflammation, mouse serum was analyzed for 
alanine aminotransferase (ALT) levels. ALT levels serve as a serum biomarker for liver 
damage, being released from damaged hepatocytes into the bloodstream [104]. When the 
mouse serum was assayed for ALT levels, male and female Zhx2WT/Afr1 and Zhx2KO/Afr1 
mice treated with CCl4 had significantly higher ALT levels than mice treated with MO 
(Fig. 3.11 A-B). Male BALBcJWT/Afr1 and BALBcJAfr1/Afr1 treated with CCl4 also have 
significantly higher ALT levels than mineral oil-treated (Fig. 3.11 C). Unexpectedly, 
Female BALBcJWT/Afr1 and BALBcJAfr1/Afr1 treated with mineral oil had significantly 
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higher ALT levels than the CCl4-treated mice (Fig. 3.11 D). There was no significant 
difference in ALT levels regardless of Zhx2 expression in male or female mice. 
3.3 Discussion 
 Studies described in this chapter tested the hypothesis that Zhx2 was responsible 
for the Hfib1 phenotype that was previously described in BALB/cJ mice. We used two 
genetic complementation approaches to test this directly. The first used BALB/cJ and 
C57BL/6J mice that have a null mutation in the Zhx2 gene. The second was a cross 
between two highly related BALB/c substrains, one with a hypomorphic Zhx2 mutation 
(BALB/cJ) and the second with a wild-type Zhx2 gene (BALB/cBYJ). Analysis of 
mRNA levels confirmed that dramatically reduced Zhx2 levels were observed in 
Zhx2Afr1/Afr1 and Zhx2Afr1/KO mice compared to their Zhx2Afr1/WT littermates in both 
cohorts. Chronic CCl4 treatment did promote fibrosis in male and female mice in both 
cohorts as determined by histological analysis, expression of the fibrotic genes ACTA2, 
Col1a1 and TIMP1, TGF and TNF levels, and serum ALT levels. However, the 
presence or absence of Zhx2 did not impact the severity of fibrosis as judged by these 
markers. Based on these results, we were not surprised that liver hydroxyproline levels 
were not affected by the absence of Zhx2. However, we did anticipate that 
hydroxyproline levels would be higher in CCl4 treated mice than in MO controls and 
cannot explain why there were no differences in these two treatment groups. Since there 
are noticeable differences in liver histology, it is possible that the assay was not sensitive 




 Data from this study indicate that the Afr1 mutation in Zhx2 is not responsible for 
the Hfib1 phenotype. This would suggest that another candidate gene within the Hfib1 
region could account for the Hfib1 trait. This region houses several genes involved in 
liver disease, including Tnfrsf11b, Colec10, DEPTOR, A1bg, Col14a1, and Has2. 
Tnfrsf11b, or osteoprotegerin, was reduced in the circulating serum in individuals with 
NAFLD [105]. In HCC, collectin liver 1 (Colec10) and alpha-1-beta glycoprotein (A1bg) 
were found to be reduced [106] [107]. Poorer prognosis in HCC has also been linked to 
the expression of the inhibitor of mTOR signaling DEPTOR [108]. Increases in both 
collagen 14a1 (Col14a1) and hyaluronan synthase 2 (Has2) have been found in liver 
fibrosis [109, 110]. Further experiments looking at the expression of, or polymorphisms 
within, these other genes could be analyzed to determine if any are viable candidates for 
Hfib1. Additionally, the CCl4 data from this experiment is highly variable, which might 
make any slight difference we see between the wild-type and Zhx2 deficient mice from 
reaching significance. Modifications in CCl4 administration or altering the fibrosis model 











Figure 3.1 Mice homozygous for the Zhx2Afr1 mutation or heterozygous Zhx2Afr1/KO 
mice display reduced Zhx2 mRNA levels. 
Zhx2 mRNA expression in male Zhx2WT/Afr1 (n=6) or Zhx2Afr1/Afr1 mice (CCl4 n=5, MO 





(CCl4 n=5, MO n=6) or Zhx2Afr1/Afr1 mice (CCl4 n=5, MO n=4), treated with either CCl4 
or MO (B). Zhx2 mRNA expression in male BALB/cJWT/Afr1 (CCl4 n=6, MO n=5) or 
BALB/cJAfr1/Afr1 mice (n=6), treated with CCl4 or MO (C). Zhx2 mRNA expression levels 








Figure 3.2 Histological analysis indicates that reduced Zhx2 expression does not 
alter fibrosis after CCl4 treatment. 
Representative histology (10x) from male and female Zhx2WT/Afr1 and Zhx2KO/Afr1 mice 
(A, B) and male and female BALB/cJWT/Afr1 and BALB/cJAfr1/Afr1 mice (C, D) with either 
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WT or reduced Zhx2, treated with CCl4 or MO for six weeks. Images shown are 































Figure 3.3 Sirius Red quantification indicates that Zhx2 expression does not alter 
fibrosis after CCl4 treatment. 
Histology (10x) from male and female Zhx2WT/Afr1 and Zhx2KO/Afr1 mice and 
BALB/cJWT/Afr1 and BALB/cJAfr1/Afr1 mice treated with CCl4 or MO for six weeks were 





fluorescence was quantified in male Zhx2WT/Afr1 (MO n=5, CCl4 n=6 ) or Zhx2KO/Afr1 
(n=6) mice, treated with CCl4 or MO (A). Sirius Red fluorescence was quantified in 
female Zhx2WT/Afr1 (n=6) or Zhx2KO/Afr1 mice (MO n=4, CCl4 n=5), treated with CCl4 or 
MO (B). Sirius Red fluorescence was quantified in male BALB/cJAfr1/Afr1 (n=6) or 
BALB/cJWT/Afr1 (n=5) mice treated with CCl4 or MO (C). Sirius Red fluorescence was 
quantified in female BALB/cJAfr1/Afr1 (MO n=6, CCl4 n=5) or BALB/cJWT/Afr1 (n=5) mice, 





Figure 3.4 CCl4-mediated increase in ACTA2 mRNA levels are not altered by the 
absence of Zhx2. 
ACTA2 mRNA expression in male Zhx2WT/Afr1 or Zhx2KO/Afr1 mice, treated with CCl4 or 





Zhx2KO/Afr1 mice (n=4), treated with CCl4 or MO (B). ACTA2 mRNA expression in male 
BALBcJAfr1/Afr1 (CCl4 n=6, MO n=5) or BALB/cJWT/Afr1 (n=6) mice, treated with CCl4 or 
MO (C). ACTA2 mRNA expression in female BALB/cJAfr1/Afr1 (CCl4 n=4, MO n=6) or 








Figure 3.5 CCl4-mediated increase in Col1a1 mRNA levels are not altered by the 
absence of Zhx2. 
Col1a1 mRNA expression in male Zhx2WT/Afr1 (n=6) or Zhx2KO/Afr1 mice (CCl4 n=5, MO 
n=6), treated with CCl4 or MO (A). Col1a1 mRNA expression in female Zhx2WT/Afr1 
(CCl4 n=6, MO n=5) or Zhx2KO/Afr1 mice (CCl4 n=5, MO n=4), treated with CCl4 or MO 
(B). Col1a1 mRNA expression in male BALBcJAfr1/Afr1 (CCl4 n=6, MO n=5) or 
BALB/cJWT/Afr1 mice (CCl4 n=6, MO n=5), treated with CCl4 or MO (C). Col1a1 mRNA 
expression in female BALB/cJAfr1/Afr1 (CCl4 n=4, MO n=6) or BALBcJWT/Afr1 mice (CCl4 








Figure 3.6 CCl4-mediated increase in Timp1 mRNA levels are not altered by the 
absence of Zhx2. 
Timp1 mRNA expression in male Zhx2WT/Afr1 or Zhx2KO/Afr1 mice, treated with CCl4 or 
MO (n=6) (A). Timp1 mRNA expression in female Zhx2WT/Afr1 (n=6) or Zhx2KO/Afr1 (CCl4 
n=5, MO n=4) mice, treated with CCl4 or MO (B). Timp1 mRNA expression in male 
BALB/cJAfr1/Afr1 (CCl4 n=5, MO n=6) or BALB/cJWT/Afr1 (CCl4 n=6, MO n=5) mice, 
treated with CCl4 or MO (C). Timp1 mRNA expression in female BALB/cJAfr1/Afr1 or 




Figure 3.7 CCl4 administration does not alter hydroxyproline levels in the liver, 
regardless of Zhx2 expression. 
Hydroxyproline levels (ug) of hydrolyzed tissue homogenate in both Male Zhx2WT/Afr1 
and Zhx2Afr1/Afr1 mice treated with CCl4 or MO (n=6) (A). Hydroxyproline levels (ug) of 





Zhx2Afr1/Afr1 (n=6) mice treated with CCl4 or MO (B). Hydroxyproline levels (ug) of 
hydrolyzed tissue homogenate in male BALB/cJAfr1/Afr1 (CCl4 n=5, MO n=6) and 
BALB/cJWT/Afr1 (n=6) given CCl4 or MO (C). Hydroxyproline levels (ug) of hydrolyzed 
tissue homogenate in female BALB/cJAfr1/Afr1 (CCl4 n=5, MO n=6) and BALB/cJWT/Afr1 





Figure 3.8 CCl4 administration does not significantly alter TNFα mRNA expression 
in the liver, regardless of Zhx2 expression. 
TNFα mRNA expression in male Zhx2WT/Afr1(CCl4 n=5, MO n=6) or Zhx2KO/Afr1 (n=6) 





or Zhx2KO/Afr1 (CCl4 n=5, MO n=4) mice, treated with CCl4 or MO (B). TNFα mRNA 
expression in male BALB/cJAfr1/Afr1 (n=6) or BALB/cJWT/Afr1 (CCl4 n=6, MO n=5) mice, 
treated with CCl4 or MO (C). TNFα mRNA expression in female BALB/cJAfr1/Afr1 (CCl4 




























Figure 3.9 CCl4 administration does alter TGF-β mRNA expression but does not 
alter with the absence of Zhx2. 
TGF-β mRNA expression in male Zhx2WT/Afr1 (CCl4 n=6, MO n=5) or Zhx2KO/Afr1 (n=6) 
mice, treated with CCl4 or MO (A). TGF-β mRNA expression in female Zhx2WT/Afr1 
(n=6) or Zhx2KO/Afr1 (CCl4 n=5, MO n=3) mice, treated with CCl4 or MO (B). TGF-β 





mice, treated with CCl4 or MO (C). TGF-β mRNA expression in female BALBcJAfr1/Afr1 








Figure 3.10 CCl4 administration does not alter TGF-β serum levels, regardless of 
Zhx2 expression. 
TGF-β serum levels in male Zhx2WT/Afr1 or Zhx2KO/Afr1 mice, treated with CCl4 (n=6) or 





with CCl4 (n=6) or MO (n=4) (B). TGF-β serum levels in male BALB/cJAfr1/Afr1 or 
BALBcJWT/Afr1 mice, treated with CCl4 (n=6) or MO (n=4) (C). TGF-β serum levels in 
female BALBcJAfr1/Afr1 or BALBcJWT/Afr1 mice, treated with mineral oil (n=4, n=3) or 











Figure 3.11 CCl4 administration does alter ALT serum levels but does not worsen 
with reduced Zhx2 expression. 
ALT serum levels in male Zhx2WT/Afr1 (CCl4 n=6, MO n=5) and Zhx2KO/Afr1 (n=6) mice, 
treated with CCl4 or MO for six weeks (A). ALT serum levels in female Zhx2WT/Afr1 (CCl4 
n=5, MO n=4) and Zhx2KO/Afr1 (CCl4 n=5, MO n=6) mice, treated with CCl4 or MO for 
six weeks (B). ALT serum levels in male BALB/cJWT/Afr1 (n=6) and BALB/cJAfr1/Afr1 
(n=6) mice, treated with CCl4 or MO for six weeks (C). ALT serum levels in female 
BALB/cJWT/Afr1 (n=6) and BALB/cJAfr1/Afr1 (CCl4 n=5, MO n=4), treated with CCl4 or 

















CHAPTER 4. CHARACTERIZATION OF THE ALPHA-FETOPROTEIN 
REGULATOR 2 (AFR2) TRAIT IN RESPONSE TO LIVER REGENERATION 
4.1 Introduction 
The liver has a remarkable ability to repair and regenerate itself in response to 
damage. In most liver diseases, regeneration is required after hepatocyte damage, 
inflammation, and fibrosis. Subsequent to damage, remaining hepatocytes must be 
signaled to proliferate to regain liver mass. This proliferation process is accomplished by 
priming the hepatocytes, resulting from increased signaling of c-jun and c-myc and the 
production of inflammatory cytokines TNF-α and IL-6 [60, 61]. This signaling cascade 
makes it possible for the transition of quiescent hepatocytes to proliferative hepatocytes. 
After the initial priming phase, growth factors, including hepatocyte growth factor (HGF) 
and endothelial growth factor (EGF), are released [62, 63]. HGF binds to mesenchymal-
epithelial transition factor (c-Met), activating downstream signaling to induce 
proliferation and decrease apoptosis [111]. EGF binds to the EGF receptor (EGFR), 
which is also required for activating proliferation [112]. The proliferation phase 
continues, in order to replace damaged or apoptotic cells, until the liver regains normal 
size; at this point, hepatocytes enter the termination phase. Although there are many 
unknowns regarding the termination of hepatocyte regeneration, TGF-β signaling has 
been found integral in blocking further hepatocyte proliferation [64]. Through this multi-
phased process, the liver can orchestrate the regeneration and repair to recover from the 
loss of hepatocytes. Understanding regeneration signaling and regulation is beneficial in 
developing new treatments for liver disease. 
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Experimentally, liver regeneration can be initiated by a variety of methods. In 
rodents, two of the most commonly used methods are partial hepatectomy (PH) and 
treatment with the hepatotoxin CCl4. PH is conducted by the removal of two-thirds of the 
liver lobes. Although these lobes do not grow back, the liver regenerates to make up for 
the loss of volume without causing any persistent liver tissue damage [113]. Metabolism 
of CCl4 by hepatic Cyp2e1 produces free radicals, which, when administered acutely, can 
cause necrosis, apoptosis, and ultimately regeneration of hepatocytes [67]. 
AFP, which is normally expressed at high levels in the fetal liver and silenced at 
birth, is transiently reactivated during liver regeneration. In fact, AFP has become a well-
characterized marker of liver regeneration. Previous studies found that the C3H/HeJ 
mouse strain exhibited greater levels of AFP mRNA after CCl4 treatment than C57BL/6J 
mice [82]. The high AFP induction in C3H/HeJ was found to be dominant to the low 
induction, and the locus controlling this trait was called alpha-fetoprotein regulator 2 
(Afr2); C3H/HeJ and C57BL/6J mice were designated as having Afr2a and Afr2b alleles, 
respectively[82]. Further QTL analysis indicated that the gene responsible for the Afr2 
trait was located on mouse chromosome 2 [92].  
Although previous studies have provided insight regarding the Afr2 trait, the Afr2 
gene has not been identified. Previous studies analyzed Afr2 in C3H/HeJ and C57BL/6J 
mice but not in other mouse strains. A better understanding of Afr2 in additional mouse 
strains could provide insight to identify the Afr2 gene. In particular, we were interested to 
know whether the Afr2b allele was unique to C57BL6/J mice or found in other C57BL 
substrains. Therefore, in this pilot study, I used CCl4 to induce liver regeneration in mice 
of six strains: 129X1/SvJ, C3H/HeJ, DBA/2J, C57BL/10SnJ, C57BL/6NJ, and 
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C57BL/6J. My results indicated that the Afr2b allele was present in all C57BL substrains, 
based on low AFP induction after CCl4 treatment, whereas the other strains contained the 
Afr2a allele. Initial studies indicated that the Afr2a allele was dominant over the Afr2b 
allele; another study suggested that these two alleles were co-dominant [114]. To further 
explore this, we analyzed AFP expression in F1 mice that were generated from a cross 
between 129X1/SvJ and C57BL/6J parents. Male and female F1 offspring at eight weeks 
of age were injected with CCl4 to induce liver regeneration. I found that F1 mice had 
intermediate levels of AFP reactivation compared to 129X1/SvJ and C57BL/6J mice, 
consistent with the Afr2a and Afr2b alleles being co-dominant. 
An additional regulator of AFP, initially called Afr1, was also found to be the 
cause of persistent AFP expression after birth in BALB/cJ mice [82]. In our lab, the Afr1 
trait was found to be due to a hypomorphic mutation in the gene Zhx2 [84]. Our lab has 
also shown that Zhx2 deficiency can significantly elevate several other genes, including 
H19, Gpc3, and LPL [84, 86, 89]. When looking at the Afr2 trait in C3H/HeJ and 
C57BL/6J mice, our lab and others have shown that both Zhx2 and Afr2 repress the same 
genes but are not genetically linked [82, 86]. We hypothesized that mice with high AFP 
reactivation would have elevated levels of Zhx2 targeted genes in this liver regeneration 
model. When looking at our data in a pilot study, H19, LPL, and Gpc3 were increased in 
mice with high AFP reactivation. Interestingly, even though eight-week-old F1 mice have 
an intermediate AFP reactivation, male mice do not have a fold increase in H19 and LPL 
while female mice do, suggesting that there might be additional sex-regulated factors 





 In an initial pilot study, six-week-old male mice from six different strains were 
injected with either MO or CCl4 in a model of liver regeneration. After 72 hours, livers 
were collected, and AFP mRNA levels were measured. 129X1/SvJ, C3H/HeJ, and 
DBA/2J exhibited significantly increased AFP levels after CCl4 treatment, having a fold 
increase of approximately 42, 46, and 42 compared to MO controls, respectively (Fig. 4.1 
A-C, Fig. 4.6 A). In contrast, much lower AFP induction was seen in C57BL/6J, 
C57BL/6NJ, and C57BL/10SnJ mice, which only had a fold increase of approximately 2, 
5, and 3 compared to MO controls, respectively (Fig. 4.1 D-F, Fig. 4.6 A). This result 
was confirmed by analyzing serum AFP levels in 129X1/SvJ, C3H/HeJ, and C57BL/6J 
mice. Male 129X1/SvJ and C3H/HeJ mice had a 42-fold and 52-fold increase in AFP 
serum levels in CCl4-treated mice compared to MO controls, respectively (Fig. 4.2). Male 
C57BL/6J mice treated with CCl4 did have an increased serum AFP of 29-fold over MO 
treated mice, but the maximum levels remained much lower than the non-C57 lineage 
mice (Fig. 4.2). 
The long non-coding RNA H19 was originally identified based on a screen for 
Zhx2-regulated genes and subsequently found to be regulated by Afr2 [114]. Additional 
genes that were identified in our lab to be targets of Zhx2, including Gpc3 and Lpl, also 
appeared to be controlled by Afr2 in C57BL/6J and C3H/HeJ mice. To test whether these 
three genes also showed the same response to Afr2 in the six strains used in my pilot 
study, their expression was analyzed. In 129X1/SvJ, C3H/HeJ, and DBA/2J mice, H19 
mRNA expression was increased by 8-, 95-, and 2.3-fold, respectively, compared to MO 
controls (Fig. 4.3 A-C, Fig. 4.6 B). H19 levels in C57BL/6J, C57BL/6NJ, and 
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C57BL/10SnJ were increased by 1.6-, 1.5- and 0.9-fold, respectively, compared to MO 
controls (Fig. 4.3 D-F, Fig. 4.6 B). The same trend was observed for Lpl; levels were 
significantly increased in the 129X1/SvJ, C3H/HeJ, and DBA/2J mice roughly 3-fold 
after CCl4 treatment (Fig. 4.4 A-C, Fig. 4.6 C). In contrast, Lpl mRNA levels in 
C57BL/6J, C57BL/6NJ, and C57BL/10SnJ increased 1.6-, 1.5-, and 0.8-fold, respectively 
(Fig. 4.4 D-F, Fig. 4.6 C). Gpc3 mRNA levels increased roughly 7- and 9-fold in 
129X1/SvJ and C3H/HeJ mice, respectively, although there was no significant difference 
in Gpc3 levels between CCl4- and MO-treat DBA/2J mice (Fig. 4.5 A-C, Fig. 4.6 D). 
C57BL/6J, C57BL/6NJ, and C57BL/10SnJ exhibited slightly decreased Gpc3 levels after 
CCl4 treatment compared to MO controls (Fig. 4.5 D-F, Fig. 4.6 D). 
Cyp2e1 is the major CCl4-metabolizing enzyme in the liver and is responsible for 
generating radicals that cause liver damage. A simple explanation for the mouse strain 
differences in AFP induction after CCl4 treatment could be differences in Cyp2e1 levels. 
We, therefore, analyzed Cyp2e1 levels in all six strains after MO treatment, in which no 
liver damage occurred. We found no significant differences in Cyp2e1 mRNA levels 
between the six groups in the pilot study (Fig. 4.7 A). Modest differences in Cyp2e1 
mRNA levels were found after CCl4 treatment, but these differences did not correlate 
with the expression of Afr2 target genes (Fig. 4.7 B). This data suggests that differences 
in Cyp2e1 levels cannot account for the Afr2 phenotype. 
 Previous studies provided conflicting data regarding the dominance of the Afr2 
alleles; initial studies indicated that Afr2a was dominant over Afr2b, whereas a second 
study indicated that these two alleles were co-dominant [82, 92]. Since 129X1/SvJ mice 
showed a robust increase in AFP levels after CCl4 treatment, we used this strain, 
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C57BL/6J, and F1 offspring between these two strains to further investigate dominance 
of the Afr2 alleles in a full liver regeneration study. Analysis was performed in mice that 
were 8 weeks of age since we found that these mice exhibited a more robust AFP 
activation than 6-week-old mice used in the pilot study. Seventy-two hours after CCl4 or 
MO treatment, male and female mice were killed, and serum and liver tissue were 
collected. Liver mRNA analysis showed that AFP mRNA levels in 129X1/SvJ mice had 
an 89-fold increase in males and a 68-fold increase in females (Figure 4.7 A, B). 
C57BL/6J mice exhibited lower AFP activation in regenerating livers, increasing 11-fold 
in males and 5-fold in females (Figure 4-7 C, D). When F1 mice were injected with CCl4, 
the activation of AFP was 26-fold in males and 28-fold in females (Figure 4-7 E, F). 
Serum AFP levels were also measured in the 8-week-old liver regeneration mice (Figure 
4-8 A-B). For both male and female mice, the increase in serum AFP levels was 
intermediate between 129X1/SvJ mice (high induction) and C57BL/6J mice (low 
induction). Taken together, these data from the full liver regeneration study indicate that 
the Afr2a and Afr2b alleles are co-dominant.  
 As with the six-week-old pilot study mice, the full study male and female 
129X1/SvJ, F1, and C57BL/6J were analyzed for gene expression of Zhx2 targets. When 
we analyzed H19, we saw a robust increase in 129X1/SvJ mice of 9-fold in males and 8-
fold in females (Fig. 4.11 A-B, Fig. 4.12 A-B). In C57BL/6J mice, H19 expression was 
minimal and increased around 2-fold for males and 3-fold for females in the liver 
regeneration model (Fig. 4.11 C-D, Fig. 4.12 A-B). Interestingly, we expected to see 
intermediate H19 expression in the F1 mice. However, we saw a pattern that differed 
between male and female mice. Male F1 mice had a minimal increase of 2-fold in H19 
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expression, similar to C57BL/6J mice (Fig. 4.11 E, Fig. 4.12 A). Females had a robust 
increase in H19 mRNA expression of 29-fold, which was even greater than the increase 
we saw in 129X1/SvJ mice. (Fig. 4.11 F, Fig. 4.12 B). When we look at LPL mRNA 
expression, we see a similar pattern. 129X1/SvJ mice had a robust increase of around 10-
fold in males and 7-fold in females mice during liver regeneration (Fig. 4.13 A-B, Fig 
4.14 A-B). C57BL/6J mice also had a minimal increase in LPL mRNA levels of 3-fold in 
males and remained the same in females (Fig. 4.13 C-D, Fig. 4.14 A-B). In F1 male mice, 
we see LPL expression that minimally increases by 3-fold, like C57BL/6J mice (Fig. 4.13 
E, Fig. 4.14 A). F1 females had a more robust increase of LPL of 9-fold, which was more 
similar to the 129X1/SvJ mice (Fig. 4.13 F, Fig 4.14 B). When looking at Gpc3 mRNA 
expression, we saw expression changes that matched the pattern of AFP expression. 
129X1/SvJ male and female mice had a Gpc3 mRNA expression increase of around 10.6 
and 8-fold (Fig. 4.15 A-B, Fig. 4.16 A-B). C57BL/6J male and female mice had a much 
lower increase of Gpc3 expression that was 4.6- and 1.43-fold greater (Fig. 4.15 C-D, 
Fig. 4.16 A-B). F1 male and female mice had fold increases and expression of Gpc3 that 
were more intermediate at 7.4- and 3-fold (Fig. 4.15 E-F, Fig. 4.16 A-B). 
 An transient increased liver weight:body weight ratio is observed in the CCl4 in a 
model of liver regeneration [115]. The full liver regeneration study was analyzed for liver 
weight:body weight ratio to determine if different strains of mice responded to CCl4 
treatment. Both male and female mice in all three strains had similar liver weight: body 




 Results in this chapter provide new insight regarding the Afr2 phenotype. My data 
from the pilot study showed that male mice from 129X1/SvJ, C3H/HeJ, and DBA/2J 
strains displayed robust AFP activation in a regeneration model, while the mice from the 
C57BL lineage (C57BL/6J, C57BL/6NJ, and C57BL/10SnJ) show minimal AFP 
reactivation. When doing a full study using an 8-week-old mouse model of liver 
regeneration with 129X1/SvJ and C57BL/6J mice, we were able to see that 129X1/SvJ 
mice displayed robust AFP activation. In contrast, C57BL/6J mice displayed much lower 
AFP levels after CCl4 injection. When F1 mice, a cross of both pairings, were injected, 
they displayed an intermediate activation of AFP. 
 From the 6-week-old initial pilot study, we determined that mice from the C57BL 
lineage (C57BL/6J, C57BL/6NJ, and C57BL/10SnJ) have the Afr2b phenotype, while 
other strains across several other lineages (129X1/SvJ, C3H/HeJ, and DBA/2J) have the 
Afr2a phenotype. This finding confirms previous literature showing that C3H/HeJ mice 
have significantly higher AFP reactivation over the C57BL/6J mice [82]. Our data from 
the pilot study additionally shows that other strains outside of C3H/HeJ mice also display 
the Afr2a trait, while other mice in the C57BL lineage continue to display the Afr2b. 
Serum AFP levels also confirmed that mice with the Afr2a trait have significantly higher 
reactivation in liver regeneration than mice from the C57BL lineage. This data supports 
that both 129X1/SvJ and C57BL/6J mice served as a suitable choice for both the Afr2a 
and Afr2b for a full 8-week-old mouse liver regeneration study, respectively. 
 It is known that Zhx2 (Afr1) and Afr2 are not genetically linked both regulate 
AFP independently of each other along with other essential liver genes [82, 86]. Our pilot 
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study data confirmed that C3H/HeJ and 129X1/SvJ mice both have increases H19, LPL, 
and Gpc3 levels, but DBA/2J mice only have an increase in LPL. This might suggest that 
the gene responsible for Afr2 might not be sufficient to alter these gene’s expression 
alone in these strains of mice and also might rely on other gene changes. 
 With the full liver regeneration study, we were able to determine that F1 mice 
have intermediate AFP activation, suggesting that the two Afr2 alleles are co-dominant. 
The AFP mRNA ΔΔCT average for 129X1/SvJ mice was 3.38, whereas C57BL/6J mice 
were 0.22. The F1 mice have an average of 1.23, falling in between those two strains. 
This data supports a previous finding that F1 offspring from C3H/HeJ and C57BL/6J 
mice have an intermediate AFP response in a model of liver regeneration [114]. Our data 
additionally shows that using other strains that have the Afr2a trait for the F1 breeding 
also results in intermediate AFP reactivation. 
The data from the pilot study suggests that the Afr2b trait is unique to the mice 
from the C57BL lineage. Identifying the point in the evolution of different inbred mouse 
strains when the Afr2b allele first appeared could help identify the causal Afr2 gene. 
Future experiments could focus on repeating the liver regeneration model with mouse 
strains closer to the branching that led to the C57 lineage, including YBR/EiJ and C58/J 
mice, to determine if this trait is present in these mice. Combined knowledge gained from 
this experiment and available sequencing might determine potential genes that could 
result in AFP regulation. 
 The full liver regeneration data suggests that the Afr2a and Afr2b alleles are co-
dominant. F1 offspring from 129X1/SvJ and C57BL/6J parental mice have an 
intermediate expression of AFP mRNA and serum levels. Using what we know from 
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these data, we potentially can breed F1 mice to map and identify the gene responsible for 
Afr2. Previous studies bred C3H/HeJ and C57BL/6J mice mapped the potential Afr2 
gene to a region on chromosome 2, but the gene responsible was never identified [92]. 
Using 129X1/SvJ and C57BL/6J mice, the offspring of two F1 mice should display AFP 
reactivation at high, intermediate, and low levels at a frequency of 25%:50%:25% [114]. 
Like the previous study, we could identify these high, intermediate, and low AFP 
activators with serum AFP and perform QTL analysis to determine a region of interest in 
the Afr2 trait. 
 Our pilot mouse data looking at H19 and LPL, and Gpc3 suggest that Afr2 does 
increase Zhx2 targets. Although DBA/2J mice do not have an increase in H19 and Gpc3, 
which might suggest additional genes that might be involved in targeting these gene’s 
expression. The data from our full mouse study suggest that 129X1/SvJ with the Afr2a 
allele have robust increases in H19, LPL, and Gpc3 levels, while C57BL/6J mice with the 
Afr2b allele have lower fold increases of these genes. F1 male and female mice with both 
alleles have intermediate levels of Gpc3. Interestingly, F1 male mice have minimal 
increases in H19 and LPL levels, where females have more significant increases. Our 
data could suggest that there could be additional sex-dependent factors that might affect 










Figure 4.1 AFP activation during regeneration is reduced in the mice from the C57 
lineage compared to other mouse strains. 
AFP mRNA expression in six-week-old male 129X1/SvJ mice treated with one MO or 
CCl4 injection (n=4) (A). AFP mRNA expression in six-week-old male C3H/HeJ mice 
treated with one MO (n=4) or CCl4 injection (n=6) (B). AFP mRNA expression in six-
week-old male DBA/2J mice with one MO (n=3) or CCl4 injection (n=5) (C). AFP 
mRNA expression in six-week-old male C57BL/6J mice treated with one MO (n=3) or 
CCl4 injection (n=6) (D). AFP mRNA expression in six-week-old male C57BL/6NJ mice 
treated with one MO (n=4) or CCl4 injection (n=6) (E). AFP mRNA expression in six-
week-old male C57BL/10SnJ mice treated with one MO (n=3) or CCl4 injection (n=6) 
(F). *p<0.05, **p<0.01, ****p<0.0001. 
 
A. B. C. 




Figure 4.2 Afr2a trait in non-C57 strains of mice significantly increases serum AFP 
levels compared to C57BL/6J mice. 
AFP serum levels male six-week-old 129X1/SvJ, C3H/HeJ, and C57BL/6J (n=4, 
C57BL/6J-MO n=3) were treated acutely with either MO or CCl4 in a model of liver 










Figure 4.3 Afr2a trait increases H19, a target gene of Zhx2, in a model of liver 
regeneration. 
H19 mRNA expression in six-week-old male 129X1/SvJ mice treated with one MO (n=4) 
or CCl4 injection (n=5) (A). H19 mRNA expression in six-week-old male C3H/HeJ mice 
treated with one MO (n=4) or CCl4 injection (n=6) (B). H19 mRNA expression in six-
week-old male DBA/2J mice treated with one MO (n=4) or CCl4 injection (n=6) (C). H19 
mRNA expression in six-week-old male C57BL/6J mice treated with one MO (n=3) or 
CCl4 injection (n=5) (D). H19 mRNA expression in six-week-old male C57BL/6NJ mice 
treated with one MO (n=4) or CCl4 injection (n=6) (E). H19 mRNA expression in six-
A. B. C. 
D. E. F. 
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week-old male C57BL/10SnJ mice treated with one MO (n=4) or CCl4 injection (n=6) 


















Figure 4.4 Afr2a trait increases LPL, a target gene of Zhx2, in a model of liver 
regeneration.  
LPL mRNA expression in six-week-old male 129X1/SvJ mice treated with one MO (n=4) 
or CCl4 injection (n=5) (A). LPL mRNA expression in six-week-old male C3H/HeJ mice 
treated with one MO (n=4) or CCl4 injection (n=6) (B). LPL mRNA expression in six-
week-old male DBA/2J mice treated with one MO (n=4) or CCl4 injection (n=6) (C). LPL 
mRNA expression in six-week-old male C57BL/6J mice treated with one MO (n=3) or 
CCl4 injection (n=6) (D). LPL mRNA expression in six-week-old male C57BL/6NJ mice 
treated with one MO (n=4) or CCl4 injection (n=6) (E). LPL mRNA expression in six-
week-old male C57BL/10SnJ mice treated with one MO (n=4) or CCl4 injection (n=6) 
(F). *p<0.05, **p<0.01. 
A. B. C. 




Figure 4.5 Afr2a trait increases Gpc3, a target gene of Zhx2, in a model of liver 
regeneration.  
Gpc3 mRNA expression in six-week-old male 129X1/SvJ mice treated with one MO 
(n=4) or CCl4 injection (n=5) (A). Gpc3 mRNA expression in six-week-old male 
C3H/HeJ mice treated with one MO (n=4) or CCl4 injection (n=6) (B). Gpc3 mRNA 
expression in six-week-old male DBA/2J mice treated with one MO (n=4) or CCl4 
injection (n=5) (C). Gpc3 mRNA expression in six-week-old male C57BL/6J mice 
treated with one MO (n=4) or CCl4 injection (n=6) (D). Gpc3 mRNA expression in six-
week-old male C57BL/6NJ mice treated with one MO (n=3) or CCl4 injection (n=6) (E). 
Gpc3 mRNA expression in six-week-old male C57BL/10SnJ mice treated with one MO 







Figure 4.6 Afr2a trait increases AFP and target genes of Zhx2 in a model of liver 
regeneration.  
AFP mRNA expression fold change in six-week-old male 129X1/SvJ, C3H/HeJ, DBA/2J, 
C57BL/6J, C57BL/6NJ, and C57BL/10SnJ mice treated with one MO or CCl4 injection 
(A). H19 mRNA expression fold change in six-week-old male 129X1/SvJ, C3H/HeJ, 







injection (B). LPL mRNA expression fold change in six-week-old male 129X1/SvJ, 
C3H/HeJ, DBA/2J, C57BL/6J, C57BL/6NJ, and C57BL/10SnJ mice treated with one 
MO or CCl4 injection (C). Gpc3 mRNA expression fold change in six-week-old male 
129X1/SvJ, C3H/HeJ, DBA/2J, C57BL/6J, C57BL/6NJ, and C57BL/10SnJ mice treated 




Figure 4.7 AFP reactivation through Afr2 is not dependent on Cyp2E1. 
Cyp2E1 mRNA expression of six-week-old male 129X1/SvJ, C3H/HeJ, DBA/2J, 





Cyp2E1 mRNA expression of male 129X1/SvJ, C3H/HeJ, DBA/2J, C57BL/6J, 
C57BL/6NJ, and C57BL/10SnJ treated with CCl4 (n=6, 129X1/SvJ, C3H/HeJ, 






Figure 4.8 F1 mice display an intermediate activation of AFP in liver regeneration. 
AFP mRNA expression in eight-week-old male 129X1/SvJ mice injected with MO (n=5) 
or CCl4 (n=7) (A). AFP mRNA expression in eight-week-old female 129X1/SvJ mice 
injected with MO (n=6) or CCl4 (n=6) (B). AFP mRNA expression in eight-week-old 






in female eight-week-old C57BL/6J mice injected with MO (n=6) or CCl4 (n=9)(D). AFP 
mRNA expression in eight-week-old male F1 mice injected with MO (n=5) or CCl4 
(n=7)(E). AFP mRNA expression in female F1 mice injected with MO (n=7) or CCl4 








Figure 4.9 F1 mice display an intermediate activation AFP in a model of liver 
regeneration. 
AFP mRNA fold change in eight-week-old male 129X1/SvJ, F1, and C57BL/6J mice 
injected with MO or CCl4 (A). AFP mRNA fold change in eight-week-old female 












Figure 4.10 F1 mice display intermediate AFP serum reactivation levels in a model 
of liver regeneration. 
AFP serum levels of eight-week-old male 129X1/SvJ, C57BL/6J, and F1 mice were 
assayed after acute treatment with mineral oil (n=5) or CCl4 (n=7, C57BL/6J CCl4 n=6) 
(A). AFP serum levels of eight-week-old female 129X1/SvJ, C57BL/6J, and F1 mice 
measured after acute treatment with mineral oil (129X1/SvJ n=6, C57BL/6J n=4, F1 n=7) 





Figure 4.11 F1 mice display an intermediate activation H19, a target of Zhx2. 
H19 mRNA expression in eight-week-old male 129X1/SvJ mice injected with MO (n=5) 
or CCl4 (n=6) (A). H19 mRNA expression in eight-week-old female 129X1/SvJ mice 
injected with MO (n=5) or CCl4 (n=6) (B). H19 mRNA expression in eight-week-old 






in eight-week-old female C57BL/6J mice injected with MO (n=5) or CCl4 (n=8) (D). 
H19 mRNA expression in eight-week-old male F1 mice injected with MO (n=5) or CCl4 
(n=7) (E). H19 mRNA expression in eight-week-old female F1 mice injected with MO 








Figure 4.12 F1 female mice display an increase in H19 expression in a model of liver 
regeneration. 
H19 mRNA fold change in eight-week-old male 129X1/SvJ, F1, and C57BL/6J mice 
injected with MO or CCl4 (A). H19 mRNA fold change in eight-week-old female 





Figure 4.13 F1 mice display an intermediate activation of LPL, a target of Zhx2. 
LPL mRNA expression in eight-week-old male 129X1/SvJ mice injected with MO (n=5) 
or CCl4 (n=6) (A). LPL mRNA expression in eight-week-old female 129X1/SvJ mice 
injected with MO (n=5) or CCl4 (n=7) (B).LPL mRNA expression in eight-week-old 






in eight-week-old female C57BL/6J mice injected with MO (n=6) or CCl4 (n=9) (D). LPL 
mRNA expression in eight-week-old male F1 mice injected with MO (n=5) or CCl4 (n=7) 
(E). LPL mRNA expression in female F1 mice injected with MO or CCl4 after injection 










LPL mRNA fold change in eight-week-old male 129X1/SvJ, F1, and C57BL/6J mice 
injected with MO or CCl4 (A). LPL mRNA fold change in eight-week-old female 







Figure 4.15 F1 mice display an intermediate activation of Gpc3, a target of Zhx2. 
Gpc3 mRNA expression in eight-week-old male 129X1/SvJ mice injected with MO (n=3) 
or CCl4 (n=5) (A). Gpc3 mRNA expression in eight-week-old female 129X1/SvJ mice 
injected with MO (n=3) or CCl4 (n=4) (B). Gpc3 mRNA expression in eight-week-old 
male C57BL/6J mice injected with MO (n=3) or CCl4 (n=5) (C). Gpc3 mRNA expression 






Gpc3 mRNA expression in eight-week-old male F1 mice injected with MO (n=3) or CCl4 
(n=6) (E). Gpc3 mRNA expression in female F1 mice injected with MO (n=3) or CCl4 







Figure 4.16 F1 mice display an intermediate increase in Gpc3 expression in a model 
of liver regeneration. 
Gpc3 mRNA fold change in eight-week-old male 129X1/SvJ, F1, and C57BL/6J mice 
injected with MO or CCl4 (A). Gpc3 mRNA fold change in eight-week-old female 





Figure 4.17 129X1/SvJ, C57BL/6J, and F1 mice respond to liver regeneration with 
CCl4. 
Liver weight/body weight ratio in eight-week-old male 129X1/SvJ mice injected with 
MO (n=5) or CCl4 (n=7) (A). Liver weight/body weight ratio in eight-week-old female 
129X1/SvJ mice injected with MO (n=6) or CCl4 (n=7) (B). Liver weight/body weight 
ratio in eight-week-old male C57BL/6J mice injected with MO (n=6) or CCl4 (n=7) (C). 
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Liver weight/body weight ratio in eight-week-old female C57BL/6J mice injected with 
MO (n=6) or CCl4 (n=9) (D). Liver weight/body weight ratio in eight-week-old male F1 
mice injected with MO (n=4) or CCl4 (n=7) (E). Liver weight/body weight ratio in female 
F1 mice injected with MO (n=7) or CCl4 (n=9) after injection at 8-weeks of age (F). 






















CHAPTER 5. SUMMARY AND FUTURE DIRECTIONS 
Inbred mice have been kept as pets and bred for their interesting phenotypes, 
including coat color, for thousands of years [70]. However, since their use in biomedical 
research, many genetic differences between different inbred strains have been observed. 
For example, well documented differences have been found between the frequently used 
substrains C57BL/6J and C57BL/6N mice. Research has shown many genetic and 
phenotypic differences between these two substrains, including differences in glucose 
tolerance and insulin secretion, making them suited for different experimentation models 
[72, 73]. Outside these substrains, many additional unique phenotypes have been 
discovered. Identifying and using genetic and phenotypic differences across strains and 
substrains of mice can be a helpful tool to gain insight into signaling pathways and 
disease. 
The data reported in this dissertation focuses on showing how two genes involved 
in AFP regulation, Zhx2 (Afr1) and Afr2, can impact liver physiology over the mouse 
species. Chapter 3 focuses on determining if the hypomorphic mutation of Zhx2 in 
BALB/cJ mice is responsible for the Hfib1 liver fibrosis phenotype. Previous research 
identified a region on chromosome 15 in BALB/cJ mice leading to increased liver 
fibrosis, overlapping with Zhx2 [84, 90]. Based on my results, I eliminated Zhx2 as the 
causal gene involved in increased fibrosis in BALB/cJ mice. Mice having diminished 
Zhx2 levels did not differ in fibrosis, inflammation, or damage markers. Chapter 4 
focuses on identifying if AFP reactivation during liver regeneration due to the Afr2 trait 
is dominant and present across different mouse strains. Previous work identified that AFP 
levels are significantly higher in response to liver regeneration in C3H/HeJ mice than 
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C57BL/6J [82]. It was determined that this was due to the monogenic Afr2 trait, which 
had two different alleles, Afr2a and Afr2b, leading to high and low levels of AFP, 
respectively [92]. My data shows that the allele responsible for diminished AFP mRNA 
and serum reactivation in a 6-week-old liver regeneration model, Afr2b, was expressed in 
mice across three strains in the C57BL lineage. The Afr2a allele leads to significant AFP 
mRNA and serum level increases in 129X1/SvJ, C3H/HeJ, and DBA/2J mice. This data 
suggests that the gene responsible for Afr2 might be mutated within the C57BL lineage, 
leading to low AFP reactivation in response to CCl4 treatment . This finding was further 
validated by conducting an 8-week- old liver regeneration model in 129X1/SvJ, 
C57BL/6J, and F1 mice that were a cross of these two strains. As expected, 129X1/SvJ 
mice had robust AFP reactivation while C57BL/6J mice did not. Interestingly, the F1 
mice displayed an intermediate level of AFP reactivation, suggesting that the both Afr2a 
and Afr2b alleles are co-dominant. Overall, this data suggests that both regulators of AFP 
have an impact on liver functioning and pathophysiology. 
5.1 Hfib1 
The data collected during the Hfib1 study suggests that the Zhx2 mutation found 
in BALB/cJ mice is not responsible for the increased fibrosis phenotype seen in this 
strain. Although, the severity of disease in the treated groups was highly variable, which 
could lead to a masking of the effect. It is possible that the variation we see is due to 
samples being taken from different lobes of the liver. In a paper from 1997, expression of 
fibrinogen genes were found to be different in each lobe [116]. In other CCl4 studies, 
inbred rat models were found to have a high level of variation between individuals [117, 
118]. A study reported that gene expression differences in pathways involved in 
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immunity, steroid metabolism, and lipid metabolism could lead to variation between mice 
in CCl4 treatment models [119]. In my study, I found that many mRNA fibrosis markers 
were varied; for example, male Zhx2KO/Afr1 treated with CCl4 had an ACTA2 mRNA 
expression average of 2.05 with a standard deviation of 1.72. With such a high standard 
deviation, the data is unreliable, and other analysis should be done. If there was a minor 
effect, the variation of this data could potentially conceal it. Several other methods for 
administration of CCl4 induce liver damage, including oral gavage, subcutaneous 
injection, and inhalation [120-122]. Unfortunately, it seems that these methods of 
administration also see variation and have more significant mortality. Treating mice with 
a lower amount of CCl4 might allow us to determine differences between the treatment 
groups. If there was some protection in mice with wild-type Zhx2, it might be 
overwhelmed by high prolonged CCl4 doses. Smaller studies looking at lower CCl4 
dosing could be potentially done in these mice to determine if there is a small effect. It is 
also possible that the number of mice (n) used in CCl4- treated groups was too small. 
Some studies have n values up to 10 to minimize variability [123]. Another option for 
reducing variability would be to change the liver fibrosis model entirely. Bile duct 
ligation (BDL) is another model for promoting liver fibrosis that is commonly used. In a 
study looking at various models for liver fibrosis induction, BDL is a consistent way of 
inducing fibrosis and liver failure within two months of surgery [124]. Although more 
invasive, this might be a better model for observing any effect that Zhx2 might have on 
the fibrosis seen in mice. 
With such high mRNA variability of fibrosis markers, additional protein analysis 
should be performed. Dr. Shirley Qiu analyzed levels of αSMA in the livers of these mice 
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but found that there were no significant differences between CCl4-treated mice (data not 
shown). Protein levels of collagen 1a1 and Timp1 could also be analyzed to determine 
any differences in fibrosis markers. 
In addition to Zhx2, many genes fall within the Hfib1 region on Chromosome 15. 
Potentially, one of these genes may be responsible for the increased fibrosis phenotype 
previously seen in BALB/cJ mice. As previously discussed, several genes within this 
region can play a role in liver fibrosis, including Col14a1 and Has2. Col14a1 (Undulin) is 
increased during liver fibrosis, found in areas of concentrated fibrosis [125]. In addition, 
Hyaluronan Synthase 2 (Has2) has been frequently observed in liver disease, with it 
being produced by the hepatic stellate cells during fibrosis. Further studies looking into 
the candidate genes in the region might determine which is responsible for the Hfib1 
phenotype. 
5.2 Afr2 
My results from the Afr2 study show that C57BL lineage mice have display low 
AFP reactivation in response to CCl4. In contrast, the other strains used in the study have 
a robust increase of AFP during liver regeneration. This finding confirms previous 
studies but further shows AFP reactivation differences across several strains [82, 92]. 
Although it is known that this Afr2 trait is involved in liver regeneration, the mechanism 
involved remains unknown. Liver regeneration is a process that happens over a few days 
and activates many pathways required for proliferation and inflammation [126]. We 
could further investigate the Afr2 trait and its mechanism of action by looking at 
129X1/SvJ and C57BL/6J mice throughout liver regeneration. Mice could have blood 
collected before the initial injection and one, three, five, and seven days post-injection to 
105 
 
monitor AFP levels in the serum. mRNA expression of markers involved in the initial 
priming process of liver regeneration, including TNF-α and IL-6, can be assessed in the 
livers of these mice soon after injection [127]. Factors associated with hepatocyte 
proliferation, including HGF and EGF, could also be assessed throughout liver 
regeneration [62]. Measuring early differences in liver damage markers, such as ALT, 
might also be informative in how much damage is occurring in these mice in the first 
several days of liver regeneration. 
In my Afr2 study looking at F1 mice, I was able to show these mice had an intermediate 
level of reactivation of AFP during liver regeneration. This data would suggest that Afr2a 
and Afr2b are co-dominant. Although it was previously thought that Afr2a was dominant, 
my data supports more recent findings that Afr2a/b mice have an intermediate phenotype 
[82, 92]. We could further use this information to map and determine the gene 
responsible for Afr2. Two F1 mice can be bred to obtain offspring that are Afr2a/a, 
Afr2b/b, and Afr2a/b. These high, low, and intermediate mice can be used to map the 
possible position of the gene responsible for Afr2. Previous studies looking at Afr2 using 
C3H/HeJ and C57BL/6J mice mapped the potential gene responsible for AFP 
reactivation in this model to a region on Chromosome 2 [92]. However, the causal gene 
was never identified. Using both the 129X1/SvJ mice and a less invasive way to screen 
large amounts of offspring through serum AFP, we should be able to remap the Afr2 
region. 
My data also found that there might be additional factors involved in the extent to 
whicgh Afr2 alters expression of genes that are also targets of Zhx2. H19 expression fold 
change was not as robust in 129X1/SvJ and DBA/2J mice compared to C3H/HeJ mice, 
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while their AFP reactivation was similar. This finding would suggest that regulation of 
H19 might require regulation besides Afr2. When looking at the 8-week-old study, H19 
and Lpl were not significantly different in the F1 male mice but were in females. This 
result might also suggest that a sex-dependent mechanism regulates these target genes. In 
previous studies, H19 was found to be female-biased in the mouse eye [128]. It has also 
been seen that increases in steroid hormones, like estrogen, cause increase H19 
expression within the tissues and were diminished in ovariectomized mice [129]. Thus, 
H19 activation in the liver in response to injury might result from an estrogen-regulated 
mechanism in this model of liver regeneration. Studies could be done to look at estrogen 
levels before, during, and after liver regeneration to test if increases in estrogen might 
play a role in increasing H19 and Lpl levels in female mice. 
5.3 Summary 
Both Zhx2 (Afr1) and Afr2 have been found to play a role within different mouse 
strains in regulating AFP expression in development and during liver injury. Zhx2 seems 
to affect the whole range of liver disease, including diet-induced fatty liver and 
hepatocellular carcinoma [89, 130]. Although my studies suggest Zhx2 is not involved in 
the extent of liver fibrosis, many other genes within the region might be responsible for 
Hfib1. AFP reactivation during liver injury is caused by the Afr2 trait [82, 92]. Although 
the gene has not been identified, my findings confirmed that the C57BL lineage has 
lower AFP activation levels than other strains and that this trait is co-dominant [92]. In 
future studies, identifying the gene responsible for the Afr2 could be of benefit. As with 
the case of Zhx2, the gene responsible for Afr2 could play a potential role in human liver 
disease. In addition, understanding more about the possible mechanisms involved in 
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